Published in final edited form as:

Curr Top Behav Neurosci. 2016 ; 28: 1–52. doi:10.1007/7854_2015_5003.

Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics

Tatiana M. Kazdoba, Prescott T. Leach, Mu Yang, Jill L. Silverman, Marjorie Solomon, and Jacqueline N. Crawley

MIND Institute, Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Room 1001A Research 2 Building 96, 4625 2nd Avenue, Sacramento CA 95817, USA

Jacqueline N. Crawley: crawley@ucdavis.edu

Abstract

Animal models provide preclinical tools to investigate the causal role of genetic mutations and environmental factors in the etiology of autism spectrum disorder (ASD). Knockout and humanized knock-in mice, and more recently knockout rats, have been generated for many of the de novo single gene mutations and copy number variants (CNVs) detected in ASD and comorbid neurodevelopmental disorders. Mouse models incorporating genetic and environmental manipulations have been employed for preclinical testing of hypothesis-driven pharmacological targets, to begin to develop treatments for the diagnostic and associated symptoms of autism. In this review, we summarize rodent behavioral assays relevant to the core features of autism, preclinical and clinical evaluations of pharmacological interventions, and strategies to improve the translational value of rodent models of autism.

Keywords

Autism; Mice; Rats; Genes; Mutant models; Social behavior; Sociability; Repetitive behavior; Cognition; Ultrasonic vocalization; Pharmacological treatment; Mouse; Preclinical; Translational; Clinical trials; Face validity; Construct validity; Predictive validity

1 Introduction

Autism spectrum disorder (ASD) includes common, impairing neurodevelopmental disorders that are present from early childhood and occur in approximately 1 % of the population (Kim et al. 2011; Elsabbagh et al. 2012). To receive an ASD diagnosis, one must exhibit symptoms from two core domains: (1) social interaction and social communication; and (2) restricted repetitive patterns of behaviors, interests, and activities. (American Psychiatric Association 2013). Associated symptoms, appearing in varying percentages of individuals, include intellectual disability, executive dysfunction, anxiety, seizures, attention deficits and hyperactivity, hyper- and hyporeactivity to sensory stimuli, and sleep disruption. The current standard of care for children is early intensive behavioral intervention (Rogers et

al. 2012; Lord and Jones 2013). Early intensive behavioral intervention is highly effective in teaching young children to overcome their social challenges, although it does not work for all, and its benefits wane with the appearance of age-related challenges in middle childhood and adolescence. Further, these behavior therapies are expensive and time-intensive, and not uniformly widely available. There is an unmet need for medical therapeutics that can be given in combination with a behavioral intervention or alone. No approved medical treatments exist for reducing or preventing the diagnostic symptoms of autism. Efficacious medications that effectively treat ASD symptoms, and specifically target social deficits, are currently under investigation.

The decision to use the term ASD in DSM-5 reflects the current thinking about the heterogeneous causes and clinical presentations of autism. A large number of de novo single gene mutations and copy number variants (CNVs) are associated with autism, each in a small number of individuals (Parikshak et al. 2013; Coe et al. 2014; Pinto et al. 2014). Environmental risk factors have been implicated, including parental age (Kong et al. 2012) and atypical maternal autoantibodies (Braunschweig et al. 2013). Analogous to “cancers,” there may be multiple “autisms,” to be defined by clustered genetic mutations with common mechanisms and treated with different classes of therapeutics. No definitive biomarkers have yet been identified across all diagnosed cases. Intensive searches are underway to define abnormalities in neurophysiology, neuroanatomy, brain chemistry, immune markers, and other potential biological abnormalities that may stratify individuals with autism, and offer outcome measures for future clinical trials (Ecker et al. 2013).

Rodent models offer preclinical tools to understand the role of genetic mutations and environmental factors in producing the diagnostic and associated symptoms of autism. Knockout (KO) and humanized knock-in mice have been generated for many of the mutations and CNVs detected in ASD and comorbid neurodevelopmental disorders such as fragile X syndrome and tuberous sclerosis (Silverman et al. 2010b; Ey et al. 2011; Baudouin et al. 2012; Zoghbi and Bear 2012; Gross et al. 2015). Several of these genetic mouse models are in use for the preclinical testing of pharmacological targets to treat the core symptoms of autism (Spooren et al. 2012; Silverman and Crawley 2014; Vorstman et al. 2014; Gross et al. 2015).

One fundamental conundrum is defining mouse behavioral assays with high relevance to the diagnostic symptoms of autism, which is a uniquely human disorder (Crawley 2004). Modeling ASD in rodents is challenging in that the clinical phenotype is heterogeneous and encompasses a wide range of behaviors. Researchers focused on developing animal models based on ASD-related behaviors benefit greatly from participating in clinical observations to obtain a comprehensive understanding of the clinical phenotypes found in individuals with ASD. We have been fortunate to observe diagnostic interviews of children with autism at the University of California Davis MIND Institute. Knowledge gained through these sessions and from lectures and conversations with many generous colleagues working with children, adolescents, and adults with autism guided our thinking in the development of analogous behavioral assays to evaluate mouse models of autism. This chapter presents state-of-the-art assays for mouse social and repetitive behaviors and reviews the preclinical progress in

evaluating hypothesis-driven pharmacological interventions, employing these behavioral assays in selected mouse models of autism.

2 Animal Models to Understand the Causes of Autism

The causes of autism are under intense investigation. Evidence supporting a large number of risk genes and CNVs at chromosomal loci is strong. Twin and family studies suggest that the genetic heritability of ASD is very high, ranging from 50 to 90 % (Ritvo et al. 1985; Smalley et al. 1988; Hallmayer et al. 2011; Miles 2011; Nordenbaek et al. 2014; Sandin et al. 2014). Genetic causes, primarily de novo mutations, have been identified in approximately 20–30 % of ASD cases, with no identified gene mutation in the majority of ASD cases (Miles 2011; Devlin and Scherer 2012; Murdoch and State 2013). Of the known genetic abnormalities associated with ASD, at least 5 % are caused by single gene mutations (Lim et al. 2013; De Rubeis et al. 2014; Iossifov et al. 2014), and at least 10 % are due to CNVs that cause structural variation, including duplications, deletions, inversions, and translocations (Marshall et al. 2008; Rosenfeld et al. 2010; Matsunami et al. 2013; Poultney et al. 2013). A remarkable preponderance of genetic mutations in ASD code for proteins mediating synaptic functions, such as those coding for the synaptic protein families SHANK (Durand et al. 2007), CNTNAP (Alarcon et al. 2008; Arking et al. 2008; Bakkaloglu et al. 2008), NLGN (Jamain et al. 2003; Laumonnier et al. 2004; Yan et al. 2005a; Talebizadeh et al. 2006; Lawson-Yuen et al. 2008), and NRXN (Kim et al. 2008). Examples of CNVs associated with ASD include chromosomal loci 15q11-q13 (Christian et al. 2008), 16p11.2 (Fernandez et al. 2010), and 22q11.21, and the *UBE3A*, *NRXN1*, and *CNTN4* genes (Fernandez et al. 2008; Kim et al. 2008; Glessner et al. 2009; Roohi et al. 2009). A subset of single gene mutations associated with ASD are responsible for other neurodevelopmental disorders, including *FMR1* in fragile X syndrome, *TSC1* in tuberous sclerosis, and *MECP2* in Rett syndrome.

Genetic and environmental risk factors identified in ASD have led to the development of many useful model systems. The best animal models display all three types of validity: construct, face, and predictive (Crawley 2004). The initial development of a new animal model may determine the extent to which construct validity leads to face validity in these models, and offers predictive validity. Construct validity requires that the animal model is generated with the same underlying biological cause, e.g., a genetic mutation, neuroanatomical abnormality, or environmental factor implicated in ASD. Face validity requires that symptoms displayed in the animal model are analogous to the human symptoms, such as social deficits and repetitive behaviors that define ASD. Predictive validity requires that treatments that are efficacious for treating the human syndrome are similarly efficacious in reversing symptoms in the animal models, such as improving social deficits or reducing repetitive behaviors. As no drug treatment has been approved for the effective treatment of the diagnostic symptoms of autism, predictive validity cannot yet be determined in animal models of ASD.

Construct validity in mouse models of autism has most frequently addressed risk genes by generating targeted mutations in the syntenic genes in the mouse genome. The number of different genetic mutations identified in ASD, each in only a few individuals (De Rubeis et al. 2014; Iossifov et al. 2014; O’Roak et al. 2014), suggests that each of these mutations may

be worthwhile to explore in mice with homologous mutations (Abrahams and Geschwind 2008; Silverman et al. 2010b; Ey et al. 2011; Spooren et al. 2012; Silverman and Crawley 2014; Wohr 2014). More recently, technological advances have enabled the development of genetically modified rats. Knockout rats (Engineer et al. 2014; Hamilton et al. 2014), as well as other species with sophisticated social behavioral repertoires, such as voles (Bales and Carter 2003a; Modi and Young 2012) and non-human primates (Bauman et al. 2014), provide additional research tools to determine how specific gene abnormalities, neurotransmission, neuroanatomical correlates, and environmental influences contribute to autism-relevant phenotypes across species.

In addition to the genetically modified rodent models of ASD, several inbred mouse strains incorporate face validity as ASD models, because they display robust and well-replicated social deficits and repetitive behaviors. These inbred strains are considered to be models of idiopathic autism, as their ASD-relevant behaviors are not caused by known genetic mutations. In assays of sociability, discussed below, the inbred strains A/J, BALB/cByJ (BALB), BTBR T^+Ipr3^{tf}/J (BTBR), C58/J (C58), and 129S1/SvImJ mice exhibited lack of sociability, as compared to inbred mouse strains with high sociability, such as C57BL/6J (B6) and FVB/NJ mice (Brodkin 2007; Moy et al. 2007; Yang et al. 2007; McFarlane et al. 2008; Moy et al. 2008b). Additionally, several mouse strains, such as BTBR and C58, also display overt motoric stereotypies or repetitive behaviors, including jumping, digging, and high levels of self-grooming and marble burying (Bolivar et al. 2007; Moy et al. 2007; Panksepp et al. 2007; McFarlane et al. 2008; Moy et al. 2008b; Yang et al. 2009; Pobbe et al. 2010; Ryan et al. 2010; Silverman et al. 2010a; Wohr et al. 2011a; Yang et al. 2012a; Burket et al. 2013; Fairless et al. 2013; Silverman et al. 2013; Han et al. 2014). Of these, BTBR has been the most extensively characterized and well-replicated for ASD-related behaviors. In addition to abnormal sociability and repetitive behaviors, BTBR mice deposit fewer scent marks and emit fewer ultrasonic vocalizations (USVs) during social interactions, display an unusual repertoire of call categories during their USVs, exhibit a lower number of complex calls (Scattoni et al. 2008; Roullet et al. 2010; Scattoni et al. 2010), and are impaired on social transmission of food preference (McFarlane et al. 2008). These inbred strains add to the genetic mouse models, along with the rat, vole, and non-human primate models of ASD, which are available to evaluate therapeutics.

3 Mouse Behavioral Assays Relevant to the Diagnostic and Associated Symptoms of Autism

3.1 Social Tests

Several behavioral assays have been developed to assess various aspects of sociability in rodents. Like humans, both mice and rats are social species that display a wide repertoire of social behaviors, engaging in intraspecies reciprocal social interactions, parenting and mating behaviors, and scent marking and aggressive behaviors (Carter et al. 1992; Miczek et al. 2001; Terranova and Laviola 2005; Arakawa et al. 2008; Silverman et al. 2010b; Kaidanovich-Beilin et al. 2011). Behavioral phenotyping can utilize many of these species-specific behaviors to address whether preclinical animal models exhibit social deficits relevant to those seen in ASD.

Reciprocal social interactions—When placed together in a confined arena, juvenile and adult pairs of mice will engage in reciprocal social interactions, participating in various types of social sniffing and physical play (Terranova and Laviola 2005; McFarlane et al. 2008; Silverman et al. 2010b). Depending on the testing parameters, juvenile or adult mice of either the same sex or opposite sex can be evaluated in dyads. Additionally, genetically modified mice can be tested with partners of the same or different genotypes. Types of social partner investigation include nose-to-nose sniffing, nose-to-body sniffing, and nose-to-anogenital sniffing. Interactions include front approach, following, chasing, physical contact such as crawling over and under each other, wrestling, and pushing past each other. Because the complex interactions of these reciprocal social interactions cannot be fully captured by automated software, individual social behaviors are typically scored by investigators using event-recording software. Several ASD-relevant genetic mouse models have been evaluated using this paradigm and were found to exhibit reduced reciprocal social interactions, including *Engrailed2* (*En2*) null mutants (Cheh et al. 2006; Brielmaier et al. 2012), conditional *Pten* mutants (Kwon et al. 2006), *Shank3* heterozygotes (Bozdagi et al. 2010; Yang et al. 2012b), and *Tsc1* heterozygotes (Goorden et al. 2007; Tsai et al. 2012). Reduced reciprocal social interactions are also seen in two inbred strains, BTBR and BALB (Bolivar et al. 2007; Panksepp et al. 2007; Yang et al. 2007; McFarlane et al. 2008).

3-chambered social approach—A well-characterized automated test of sociability is our simplified three-chambered social approach task, which offers a high-throughput approach for assessing sociability (Nadler et al. 2004; McFarlane et al. 2008; Yang et al. 2011; Silverman et al. 2012, 2013). In this task, a subject mouse is assessed for its exploration of a novel mouse (e.g., a novel social stimulus) versus a novel object. The novel mouse is typically confined by an inverted wire pencil cup, which allows for visual, auditory, olfactory, and some tactile stimuli between the novel mouse and the subject mouse. An identical inverted wire pencil cup serves as the novel object, either alone or with an inanimate object inside. Mice that display species-typical sociability will spend more time in the side chamber with the novel mouse than in the side chamber with the novel object. Sociability is further defined more specifically by more time sniffing the novel mouse than sniffing the novel object. Chamber time is calculated automatically in a photocell-equipped apparatus, where beam breaks count chamber entries as a measure of locomotor activity. Videotracking systems can perform the same functions by defining zones around the cup or similar container (Ahern et al. 2009; Silverman et al. 2015). Many lines of mice with targeted mutations in risk genes for autism, as well as inbred strains, have been evaluated in the three-chambered social approach task (Moy et al. 2006; Moy and Nadler 2008; Moy et al. 2009; Silverman et al. 2010b; Patterson 2011; Qiu et al. 2012; Jiang and Ehlers 2013). Many genetic models of ASD were reported to exhibit low sociability in this assay including GABA_A receptor *Gabrb3* KO mice (DeLorey et al. 2008), conditional *Pten* KO mice (Kwon et al. 2006), haploinsufficient *Pten* mutant mice (Page et al. 2009; Clipperton-Allen and Page 2014), *Ube3a* triplication mice (Smith et al. 2011), *Cntnap2* KO mice (Penagarikano et al. 2011), 15q11–13 duplication mice (Nakatani et al. 2009), and 17p11.2 duplication mice (Molina et al. 2008). In addition, BTBR, BALB, and C58 mice display low levels of sociability in the social approach assay (Brodkin et al. 2004; Brodkin 2007; Moy et al. 2007;

Yang et al. 2007; McFarlane et al. 2008; Moy et al. 2008b; Yang et al. 2009; Ryan et al. 2010; Silverman et al. 2010a, 2012a, 2013).

Partition test—The partition task is another straightforward assay for assessing sociability in mice, utilizing a perforated partition to separate a subject mouse from a target mouse. Similar to social approach, the subject mouse is exposed to visual, auditory, and olfactory stimuli from the target mouse, but the two mice do not physically interact. Social interest is represented by the time spent near the partition by the subject mouse. Paylor and coworkers often conduct the partition test first and then remove the partition to evaluate reciprocal social interactions in a habituated environment (Spencer et al. 2005).

Social recognition and social memory can be evaluated through the sequential use of different social partners in the partition task and in the three-chambered social approach apparatus (Moy et al. 2007; Arakawa et al. 2008). Given that mice are novelty-seeking, the subject mouse displays recognition of social novelty if it approaches and spends more time at the partition near the novel mouse as compared to the partition near the familiar mouse (Kudryavtseva 2003; Spencer et al. 2011). Similarly, in the three-chambered social approach task, social recognition is demonstrated if the subject mouse spends more time with a second novel mouse than with the previously novel but now familiar mouse. Adding delay periods of minutes or hours between presentations of the same and novel partners permits evaluation of social memory (Bielsky and Young 2004). Several genetically modified mice that exhibited reduced reciprocal social interactions or low sociability in three-chambered social approach also displayed a lack of preference for social novelty. Others were normal on social approach but failed on preference for social novelty (Moy et al. 2006; Moy and Nadler 2008; Moy et al. 2009; Silverman et al. 2010b; Patterson 2011; Qiu et al. 2012; Jiang and Ehlers 2013), including *Fgf17* KO mice (Searce-Levie et al. 2008), *Gabrb3* KO mice (DeLorey et al. 2008), and *Nlgn4* KO mice (Jamain et al. 2008). Other genetic mouse models, such as *Nlgn3* KO mice (Radyushkin et al. 2009), demonstrated reduced social novelty, but did not have deficits in other aspects of sociability. Qualitatively divergent findings on social approach versus social recognition and social memory in several models reinforce the interpretation that sociability is distinct from social recognition memory, especially in the 3-chambered assay.

Visible burrow—Mice will typically form colonies that include shared nests composed of underground burrow and tunnel complexes (Lloyd 1975; Bouchard and Lynch 1989). Large visible burrow systems are enclosures that capitalize on the mouse social structure to investigate social interactions in a seminatural habitat using a series of tunnels, burrows, and a large open surface area (Blanchard et al. 1995, 2001). Compared to the social B6 strain, BTBR mice participate in fewer interactive behaviors, such as huddling and following, in the visible burrow system while spending more time alone and engaging in increased self-grooming (Pobbe et al. 2010).

Social transmission of food preference occurs when a subject mouse, after interacting with a cagemate that recently consumed a novel food, eats more of that novel food (Galef 2003; Wrenn et al. 2003; Wrenn 2004; Ryan et al. 2008). In addition to low sociability in several

social tasks, BTBR mice also exhibit reduced social transmission of food preference (McFarlane et al. 2008).

Social dominance is measured in a tube task. Mice of two different genotypes with approximately similar body weights are placed in opposite ends of a long, narrow plastic tube. A socially dominant mouse is characterized as the mouse that advances past the halfway point of the tube or pushes the opposing mouse out of the tube. Tube test deficits in social dominance have been detected in mice with mutations in *Dvl1* (Lijam et al. 1997; Long et al. 2004), the serotonin transporter (Kerr et al. 2013), *Fmr1* (Spencer et al. 2005) and others, while 17p11.2 duplication mice exhibited increased dominant behavior in this assay (Molina et al. 2008).

Assessment of sociability in two or more cohorts of animals using multiple assays increases the strength of findings, by generating a more complete behavioral profile, assessing generalizability, and evaluating robustness and replicability. Robust, easily replicated social deficits in mutant lines of mice can then serve as primary preclinical models for the development of novel therapeutics.

3.2 Social Communication

Communication impairments are a hallmark of autism (Lord et al. 2000; Kim et al. 2014b). Depending on the intellectual ability of the individual, communication deficits can manifest as the absence of speech, language delay, the use of odd prosody and intonation, stereotyped speech, perseverative phrases, and difficulties with language pragmatics such as those involved in initiating and maintaining appropriate and meaningful conversations (Rapin and Dunn 2003).

Rodents communicate primarily through olfactory pheromones. However, mice and rats also emit vocalizations in the ultrasonic range during social interactions, and also in non-social contexts (Chabout et al. 2012). Extensive research has been done to identify components of rodent USVs that might be analogous to human language communication. The utility of USV emissions for modeling aspects of social communication deficits in autism is being extensively investigated by several laboratories. Determining whether mouse USV calls have a communication function during specific types of social interactions is a work in progress.

Mouse and rat pups emit USVs when separated from the mother and the nest (Ehret 2005). Pup USVs reliably elicit maternal retrieval (D'Amato et al. 2005; Fischer and Hammerschmidt 2011; Okabe et al. 2013) and are therefore thought to represent a communicatory signal emitted by pups at an age when they solely depend on the dam for thermoregulation and feeding. Separated pups emit even more USVs after a brief reunion period with the mother, followed by a second separation. This phenomenon, called “maternal potentiation”, has been found in both mice and rats and has been used as a measure of attachment (Shair et al. 2014). Mouse pups with a null mutation in the μ -opioid receptor gene (*Orpm*^{-/-}) emitted fewer USVs when separated from the mother and did not exhibit maternal potentiation, reflecting deficits in attachment (Moles et al. 2004). In mice, pup call numbers peak between postnatal days (PND) 7 and 9 and diminish around the age of hearing onset (PND12) (Ehret 2005; Adise et al. 2014), suggesting that pup USVs are

produced by innate mechanisms without a requirement for auditory feedback. It may be reasonable to suggest that pup USVs are a useful measure of physical development, reactivity to stress, anxiety, and attachment. However, since pup calls are likely more analogous to infant crying, quantitative and qualitative components of pup USVs are less likely to serve as a useful proxy for human language communication.

Juvenile and adult mice emit USVs during same-sex social interactions (Maggio and Whitney 1985; D'Amato and Moles 2001; Panksepp et al. 2007; Scattoni et al. 2011; Hammerschmidt et al. 2012). Pretest social isolation is usually a prerequisite for eliciting USVs in same-sex pairs. Currently, there is no practical method to differentiate calls from the two interacting animals. In juveniles, emission of USVs was positively correlated with social behaviors during juvenile social interaction (Panksepp et al. 2007), suggesting that USVs may be an affiliative component of the juvenile social repertoire. Adult mice emit large numbers of calls during same-sex interactions, following a short period of isolation. Female mice with null mutations in the *Shank2* gene emitted fewer calls as compared to wild-type females (Poultney et al. 2013). Adult male and female mice with null mutations of *Neurologin4* emitted similar numbers of calls as compared to the wild-type controls (Ey et al. 2012). Calls emitted by the resident female during the resident–intruder paradigm have been used as a measure of social memory (D'Amato and Moles 2001).

Male–female social interactions have the advantages of not requiring pretest social isolation and a greater certitude that most calls are emitted by the male (Whitney et al. 1973; White et al. 1998; Wang et al. 2008; Sugimoto et al. 2011). The number of USVs emitted by a subject male in the presence of an estrus female has been widely used as an assay for social communication in mouse genetic models of autism (Ey et al. 2012; Yang et al. 2012b; Sowers et al. 2013).

Fresh female urine and other social odors are similarly effective in eliciting USVs from adult male mice (Nyby et al. 1977; Whitney and Nyby 1979; Byatt and Nyby 1986; Holy and Guo 2005; Hoffmann et al. 2009; Malkesman et al. 2010; Roullet et al. 2011; Wohr et al. 2011b). Playback studies indicate that female mice prefer male USVs over pup USVs, artificial control sounds, or silence (Hammerschmidt et al. 2009; Shepard and Liu 2011) and prefer vocalizing males over devocalized males (Pomerantz et al. 1983), suggesting that male USVs may have a role in facilitating courtship. Recent evidence indicates that male mice exhibit abrupt changes in call repertoires when the female stimulus mouse was removed (Hanson and Hurley 2012; Yang et al. 2013), suggesting that vocal flexibility may reflect the ability to detect sudden changes in salient social cues.

Distinct call categories have been cataloged within the highly complex structures of USVs (Holy and Guo 2005; Scattoni et al. 2011). The pioneering study by Holy and Guo (2005) catalyzed recent research on categorical analysis of mouse USVs. Most investigators classify calls by visually inspecting spectrograms of recorded USVs. Currently, there is no consensus on the number of categories or the definition of each category, with the number of categories ranging from three (Hammerschmidt et al. 2012) to fifteen (Mahrt et al. 2013). Recent electrophysiological recording studies have demonstrated that neurons in the mouse auditory

midbrain respond differently to different call types (Mayko et al. 2012), highlighting the importance of categorizing calls in a manner that is biologically meaningful to mice.

Are USVs in adult mice relevant to human language? Recent studies indicate that call patterns are similar between deaf mice and hearing controls (Hammerschmidt et al. 2012; Mahrt et al. 2013) and that cross-fostering failed to change strain-specific call patterns (Kikusui et al. 2011), suggesting that mouse USVs are not acquired through auditory feedback. It may be more reasonable to suggest that USVs are an important indication of responsivity to social stimuli during social interactions, but are not highly analogous to communicatory functions of complex human language.

3.3 Motor Stereotypies, Repetitive Behaviors, and Restricted Interests

The second ASD diagnostic symptom domain includes motor stereotypies, repetitive behaviors, insistence on sameness, and restricted interests (American Psychiatric Association 2013). Motor stereotypies in ASD include hand flapping and toe walking. **Stereotypies** in mice are species-typical behaviors such as circling and jumping, which occur with frequencies considerably higher than typical levels. Behavioral stereotypies can be assessed in the home cage or observed in an empty cage, by a trained investigator using an event recorder (Crawley 2012). Many genetic models of autism exhibit motor stereotypies. For instance, *Ngn4* KO mice exhibited increased circling behavior (El-Kordi et al. 2013) and C58 mice exhibited high levels of jumping behavior (Moy et al. 2008b; Ryan et al. 2010; Silverman et al. 2012). *Gabrb3* KO mice showed high levels of circling behaviors (Homanics et al. 1997; DeLorey et al. 2008).

Repetitive self-grooming in mice has face validity to repetitive behaviors in ASD, such as assembling the same puzzle or playing one video game repeatedly. Normal patterns but unusually long bouts of self-grooming have been demonstrated in several mutant mouse models of autism, including *Shank3* (Peca et al. 2011), *Cntnap2* (Penagarikano et al. 2011), *Neurexin1a* (Etherton et al. 2009), and *Neuroligin1* (Blundell et al. 2010). High levels of self-grooming have been well-replicated in the BTBR mouse model of idiopathic autism (Yang et al. 2007; McFarlane et al. 2008; Yang et al. 2009; Pobbe et al. 2010; Silverman et al. 2010a; Amodeo et al. 2012, 2014b; Zhang et al. 2015), while the BALB inbred mouse line does not display repetitive self-grooming (Silverman et al. 2010b). Recent work in transgenic rats reported perseverative chewing behavior in *Fmr1* KO rats (Hamilton et al. 2014). Higher levels of **marble burying** are considered to reflect a repetitive behavior (Thomas et al. 2009). Marble burying relies on the species-typical burying of small objects placed into the cage. Higher marble burying was detected in BTBR (Amodeo et al. 2012; Silverman et al. 2012) and several mutant models (Silverman et al. 2010b), including *Tsc2* KO mice (Reith et al. 2013) and monoamine oxidase (MAO) A and A/B KO mice (Bortolato et al. 2013).

Versions of **open field holeboard exploration** are under development to model autism-relevant restricted interest/perseverative behaviors. Unusual hole board exploration was reported in BTBR and NMDA receptor (*Grin1*) mutant mice using olfactory cues (Moy et al. 2008a), and in MAO A and A/B knockout mice without olfactory cues (Bortolato et al. 2013).

Cognitive rigidity in autism has been modeled in several rodent models of autism. Morris water maze reversal learning assesses the ability of a mouse trained to locate a hidden platform in a pool of water to inhibit its previously learned navigation responses and learn a new platform location. Mice first learn the location of a hidden platform in a large pool of opaque water over the course of several days. After mice reach a criterion level of performance (i.e., latency under 15 s), the hidden platform is moved to the opposite side of the pool so that attempts to find the platform in the previous location must be suppressed and a new goal-directed behavior emerges for successful escape from the water. Two other versions of **maze reversal** are available: spontaneous alternation on a Y-maze, where reduced numbers of alternations between the two arms might represent perseverative behavior, and **rewarded T-maze reversal**, where the rewarded response shifts from the initial location of a food reinforcement located at one end of the T to the other end of the T. Other related tasks include extinction of fear conditioning, where a discrete cue previously paired with an aversive footshock is presented continuously without a footshock pairing, until the species-typical freezing response is attenuated. Deficits on some of these reversal tasks have been reported in BTBR (Moy et al. 2007; Yang et al. 2012a), 15q11-13 duplication (Nakatani et al. 2009), MAO A and A/B KO mice (Bortolato et al. 2013), and in eIF4E overexpressing mice (Santini et al. 2013). Similar to results of Morris water maze reversal tasks, MAO A and A/B KO mice also had decreased alternations in a forced-choice alteration T-maze (Bortolato et al. 2013) and BTBR showed deficits in water T-maze reversal (Guariglia and Chadman 2013).

Intellicages offer a home cage approach to test conditioned place preference learning and reversal, which showed a significant reversal-specific effect of valproic acid (VPA) in B6 mice, but not BALB mice (Puscian et al. 2014). Further, a **set-shifting** assay (Birrell and Brown 2000) showed a compound discrimination reversal deficit in Reeler heterozygous mice (Macri et al. 2010). An assay which employed alternation learning, followed by non-alternation learning, followed by reversal learning, used an H-shaped maze to demonstrate that tryptophan hydroxylase 2 mutants showed perseveration when the reinforcement contingencies changed (Del'Guidice et al. 2014).

The **five-choice serial reaction time task** (5-CSRTT) affords a robust measure of perseveration. The subject mouse pokes its nose into one of five holes at the front of an operant chamber, based on a stimulus presentation located in one of the five possible locations. Perseverative behavior is defined as choosing the previously rewarded stimulus location instead of choosing the currently active location. Mice with mutations in genes coding for the muscarinic acetylcholine receptor M1 and the NMDA receptor subunit Grin1 displayed perseverative deficits in 5-CSRTT (Bartko et al. 2011; Finlay et al. 2014). Despite the broad range of autism-relevant phenotypes displayed by BTBR mice, BTBR did not show perseverative behavior as assessed by the 5-CSRTT (McTighe et al. 2013).

3.4 Associated Symptoms

In addition to the core deficits associated with an autism diagnosis, there are several associated symptoms that commonly occur as comorbid conditions. A recent meta-analysis found that around 40 % of individuals with an ASD had elevated and clinically relevant

symptoms of an **anxiety disorder** (van Steensel et al. 2011). Specific phobias were the most common anxiety disorder, occurring in approximately 30 % of autistic individuals, while obsessive-compulsive disorder and social anxiety disorder/agoraphobia occurred in 17 % of autistic individuals (van Steensel et al. 2011). Common rodent behavioral tasks for the assessment of anxiety-like behaviors are the elevated plus-maze and light ↔ dark exploration. These tasks rely on the conflict between the tendency of mice to explore a novel environment versus avoidance of brightly lit open areas. Mice generally enter and spend less time in the two open arms of an elevated plus-maze as compared to the two enclosed maze arms. Mice generally spend less time in the brightly lit compartment of the light ↔ dark apparatus and make fewer transitions between the brightly lit and dark compartments. Anxiolytic drugs selectively increase the number of open arm entries and time in the open arms in the elevated plus-maze, and increase time in the light compartment and number of transitions between compartments in the light ↔ dark apparatus, confirming predictive validity (Crawley 1985; Cryan and Sweeney 2011). Other less widely used tests that detect effects of anxiolytic drugs include the operant-based Geller-Seifter and Vogel conflict assays, vocalizations emitted by pups separated from their dams to model separation anxiety (Insel et al. 1986), and marble burying, which has been described as a model of obsessive-compulsive disorder (Thomas et al. 2009).

Seizure disorders are very common in autism. At least 20 % of individuals who meet the diagnostic criteria for autism experience seizures (Volkmar and Nelson 1990). Several genetic mouse models of autism recapitulate aspects of the increased seizure susceptibility, including mice with mutations in *Synapsin1* (Greco et al. 2013), *En2* (Tripathi et al. 2009), *Cntnap2* (Penagarikano et al. 2011), *Tsc1* (Meikle et al. 2007) and *Tsc2* (Zeng et al. 2011), *Gabrb3* (DeLorey et al. 2011; Homanics et al. 1997), and *Fmr1* (Chen and Toth 2001).

Intellectual disability is present in approximately 30–40 % of ASD subjects (Matson and Shoemaker 2009; Perou et al. 2013). Learning and memory deficits have been demonstrated in several mouse models of autism, often along with electrophysiological abnormalities detected in hippocampal slice assays. Water maze and fear conditioning deficits were reported in mice with mutations in *Pten*, *Tsc1*, *Shank3*, *Cntnap2*, *En2*, and in the BTBR inbred strain, among others (Upchurch and Wehner 1988; The Dutch-Belgian Fragile et al. 1994; D’Hooge et al. 1997; Paradee et al. 1999; Goorden et al. 2007; Moy et al. 2007; MacPherson et al. 2008; Baker et al. 2010; Penagarikano et al. 2011; Brielmaier et al. 2012; Sperow et al. 2012; Yang et al. 2012a, b; Scattoni et al. 2013).

Sleep disorders are common in children with ASD. As many as two-thirds of autistic individuals may have some kind of sleep disorder (Richdale 1999). Sleep patterns and circadian rhythms have not been extensively reported in mouse models of autism. Mutant mice lacking *Cadps2*, located in the 7q autism susceptibility locus, showed an aberration in intrinsic sleep-wake cycle maintenance (Sadakata et al. 2007). *Fmr1* KO mice demonstrated abnormal circadian activity patterns, which may suggest alterations in sleep-wake cycle stability (Baker et al. 2010). *Gabrb3* KO mice exhibited differences in activity-rest neural activity as assessed by EEG (DeLorey et al. 1998).

Attention deficits and hyperactivity are a commonly associated symptom of autism. Several mutant mouse models of autism display higher exploratory locomotion in the open field test, including *Fmr1* (Kramvis et al. 2013), *Cntnap2* (Penagarikano et al. 2011), *ProSAP1/Shank2* (Schmeisser et al. 2012), and a 16p11.2 deletion (Portmann et al. 2014).

Sensory symptoms, including under- and over-responsivity to sensory stimuli, are frequently found in those with ASD (Rogers and Ozonoff 2005). Idiosyncratic overreaction to a sudden loud noise can be tested in mice by assessing response to acoustic stimuli at various decibel levels. An increased response to sensory stimuli was observed in *Fmr1* mice (Chen and Toth 2001). Reduced acoustic startle was reported in several other mutant mouse models of autism including *Gabrb3* (DeLorey et al. 2011), *EphrinA* (Wurzman et al. 2014), and female *Mecp2* heterozygotes (Samaco et al. 2013). Idiosyncratic underreaction to painful stimuli can be assessed in mice with hot plate or tail flick thermal stimuli. Genetic models of autism have revealed increased sensitivity in these nociceptive tasks in *Gabrb3* KO mice (DeLorey et al. 2011).

Mouse behavioral assays described above have proven useful in phenotyping genetic mouse models of autism. Approaches to develop ideal models of ASD may utilize multiple species to ensure that the same outcomes are present across species, to best advance the potential for an integration of systems neuroscience with the human syndrome. Successful multiple species approaches will contribute to fast-forwarding our progress to develop effective mechanism-based therapeutics. Mouse models provide relatively low cost, high-throughput, valid phenotypes in various behavioral assays relevant to the diagnostic symptoms of ASD.

Comparative studies utilizing rodent vole models are another powerful approach for modeling social behavior relevant to ASD. Prairie and pine voles (*Microtus ochrogaster* and *Microtus pinetorum*, respectively) are a monogamous species living in highly social burrows (Carter and Getz 1993; Carter et al. 1995). In contrast, montane and meadow voles (*Microtus montanus* and *Microtus pennsylvanicus*, respectively) are non-monogamous and often live in social isolation. Differences in oxytocin peptide and receptor binding have been reported between these species of vole and are functionally related to their differences in social behavior (Winslow et al. 1993; Young et al. 2002). Carter, Bales, and colleagues have reported both facilitation and deleterious effects of oxytocin administration in voles in the partner preference pair bonding assay. These effects were both sexually dimorphic and developmentally specific (Bales and Carter 2003a, b; Carter et al. 2009; Bales et al. 2013). Intranasal oxytocin paradigms developed in the vole have recently been examined in mouse models, with reports of either adverse or minimally beneficial behavioral outcomes, dependent on length of exposure (Bales et al. 2014; Huang et al. 2014). Novel pharmacology using vole models recently illustrated that d-cycloserine, a partial agonist of the *N*-methyl-D-aspartate (NMDA) glutamate receptor that enhances receptor activation in the presence of glutamate, dose dependently enhanced partner preference in female prairie voles (Modi and Young 2011).

Rats have sophisticated behavioral repertoires which make this rodent species excellent for modeling the nuances of complex social behavior. Recent advances in genetic technologies allow for manipulation of rat gene expression. Two genetic models with relevance to ASD

have been generated. One example is a rat knockout of the *Fmr1* gene, which is associated with fragile X syndrome. Behavioral phenotyping revealed that *Fmr1* KO rats have low levels of social play behavior and higher levels of a repetitive block chewing (Hamilton et al. 2014). Other genetic ASD-relevant rat KO models are the neuroligin-3 (*Nlgn3*) null and the neurexin-1α (*Nrxn1-α*) KO rats model. *Nlgn3* KO rats display reduced juvenile social play (Hamilton et al. 2014), while *Nrxn1-α* KO rats exhibit hyperactivity, exaggerated startle responses, and impairments in latent inhibition and spatial-dependent learning (Esclassan et al. 2015). Genetic rat models of autism offer a new set of tools for evaluating pharmacological interventions.

Several studies suggest a role for environmental factors, in combination with genetic susceptibility, in the etiology of ASD. An impressive population-based Danish study in 2013 outlined prenatal exposure to the anticonvulsant VPA, but not to other anti-seizure medications, nearly tripled the risk of ASD (Christensen et al. 2013). The larger study confirmed an earlier smaller report that exposure to VPA during gestation increased relative risk for ASD and maladaptive ASD-related behavioral dysfunction in children born to women who took VPA to treat their epilepsy (Bromley et al. 2008). Mouse models exposed to gestational VPA recapitulate selective behavioral and electrophysiological deficits analogous to those seen in the clinic (Wagner et al. 2006; Gandal et al. 2010; Mehta et al. 2011). Similarly, rats exposed to VPA in utero show increased frequency of motor stereotypies in adolescence, reduced social exploration, and low levels of juvenile rough and tumble play supporting the validity of this model (Schneider and Przewlocki 2005). Although the mechanisms underlying the link between VPA and autism are not fully understood, prenatal exposure to VPA alters GABA and monoamine systems, induces a loss of specific subsets of neurons, and acts through epigenetic mechanisms via histone deacetylase inhibition (Bambini-Junior et al. 2014).

Excitatory–inhibitory imbalance is a prominent hypothesis for the etiology of ASD. Pharmacological interventions that shift the balance closer to normal are under consideration. Acute exposure to the glutamate antagonist, MPEP, reduced marble burying phenotypes in offspring of dams treated with VPA, but did not alleviate anxiety-like behavior (Mehta et al. 2011). GABAergic neurons switch from excitatory to inhibitory during key developmental processes. This sequence was reported to be absent in hippocampal CA3 neurons of offspring of VPA-treated rat dams (Tyzio et al. 2014). Moreover, VPA-treated offspring emitted low numbers of isolation-induced pup USVs. Bumetanide pretreatment to dams rescued the GABA developmental impairments and restored call emissions in VPA rodent offspring (Tyzio et al. 2014).

The first non-human primate model of ASD involved the bilateral removal of the medial temporal lobe of young rhesus macaque monkeys. Normal infant monkeys develop strong affiliative bonds. Lesioned subjects displayed atypical dyadic social interactions at 2 and 6 months and exhibited aberrant stereotypies (Bachevalier 1994; Bachevalier et al. 2001). Other lesion studies produced selective amygdala lesions in 2-week-old macaques. By 6–8 months of age, the lesioned animals demonstrated substantial fear behaviors during dyadic social interactions while maintaining much of the age-appropriate repertoire of social behavior (Prather et al. 2001).

Other reported non-human primate models of ASD have tested the hypothesis that exposure of the fetal brain to maternal autoantibodies during gestation increases ASD risk. Rhesus monkeys exposed to human immunoglobulin collected from mothers of multiple children diagnosed with ASD consistently demonstrated increased whole-body stereotypies and hyperactivity across multiple testing paradigms (Martin et al. 2008). In extended studies, these monkeys consistently deviated from species-typical social norms by more frequently approaching familiar peers in a social approach paradigm (Bauman et al. 2013).

Oxytocin administration in rhesus macaques was reported to significantly increase plasma oxytocin concentrations when administered using the aerosol or intranasal routes (Modi et al. 2014). Social perception in the dot-probe task in monkeys receiving intranasal oxytocin detected selectively reduced attention to negative facial expressions, but not neutral faces or nonsocial images (Parr et al. 2013). This first pharmacological report using non-human primates provides promising evidence for oxytocin-based compound efficacy in clinical populations.

4 Evaluating Pharmacological Therapeutics in Animal Models with High Construct Validity and Strong Face Validity for ASD

Clinical trials for ASD core symptoms are challenged by the heterogeneity of the disorder, which can limit study design parameters and statistical power for outcome measures. Currently, there are no pharmacotherapies approved by the US Food and Drug Administration specifically for social interaction, communication deficits, and repetitive behaviors. The only FDA-approved pharmacological treatments for autism are the antipsychotics risperidone and aripiprazole, which treat the associated irritability symptoms of aggression, self-injury, and temper tantrums. Greater than 50 % of children diagnosed with ASD in the USA are using at least one psychoactive drug (Spencer et al. 2013), as prescribed for irritability (Siegel and Beaulieu 2012), or given off-label. Risperidone, which modulates dopamine and serotonin systems, had a significant effect on stereotyped behavior in children with ASD (McCracken et al. 2002; McDougle et al. 2005; Chavez et al. 2006), although this was not seen in all studies (Ghaeli et al. 2014). Risperidone studies that included behavioral scales measuring aspects of sociability, such as social relationships and language, had large effect sizes, but failed to reach statistical significance (McDougle et al. 2005). Other studies that utilized additional behavioral scales, such as the Aberrant Behavior Checklist Social Withdrawal subscale and the Childhood Autism Rating Scale (CARS), found that risperidone treatment was effective compared to placebo (Scahill et al. 2013; Ghaeli et al. 2014). The lack of consistency for risperidone's effects on aspects of social behavior may be due to clinical heterogeneity within the studies' ASD subject population, differences in treatment duration, as well as differences in the tools used for sociability outcome measures. Treatment studies with antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, have yielded mixed results on improvement of repetitive behaviors. For example, SSRI treatment with fluoxetine or citalopram did not produce a clinically significant improvement on repetitive behaviors in children (Hollander et al. 2005; King et al. 2009). However, additional studies with fluoxetine and fluvoxamine demonstrated improvement on repetitive thoughts, repetitive

actions, and scores of an obsessive–compulsive scale in adults (McDougle et al. 1996; Hollander et al. 2012), suggesting that SSRI treatment approach may depend on the age of individuals with ASD.

As described in Table 1, additional classes of compounds have been evaluated for their efficacy in treating ASD core symptoms, although large-scale, randomized, double-blind, placebo-controlled trials are lacking. Administration of oxytocin, a neuropeptide involved in social pair bonding, social memory, and affiliative behaviors (Gimpl and Fahrenholz 2001), increased social awareness and emotional recognition in both neurotypical individuals and those with ASD in pilot studies (Hollander et al. 2007; Bartz and Hollander 2008; Rimmele et al. 2009; Bartz et al. 2010; Guastella et al. 2010). Interestingly, functional neuroimaging results from a randomized, double-blind cross-over study in children with ASD found that brain structures associated with sociability (e.g., striatum, posterior cingulate, and premotor cortex) showed greater recruitment after intranasal oxytocin administration, suggesting that this neuropeptide enhanced the saliency of social stimuli (Gordon et al. 2013).

STX209 (Arbaclofen), a selective GABA_B agonist thought to stimulate inhibitory neurotransmission, was evaluated as a treatment for fragile X syndrome, a neurodevelopmental disorder with a high incidence of ASD comorbidity (Berry-Kravis et al. 2012). Although there were no statistically significant differences in the primary outcome (Aberrant Behavior Checklist-Irritability subscale), male subjects were noted as having positive improvements on several global measures including socialization scores. Additionally, in a study with individuals with ASD, Arbaclofen was well tolerated and improved scores on social responsiveness, social withdrawal, and clinical global impression scales (Erickson et al. 2014a).

D-cycloserine, a partial agonist of the ionotropic glutamatergic NMDA receptor, has been evaluated in one single-blind, placebo-controlled trial, where the majority of children with ASD treated with D-cycloserine improved their scores on the Autistic Behavior Checklist Lethargy and Social Withdrawal subscale (Posey et al. 2004). Memantine, an NMDA receptor antagonist approved for Alzheimer's disease, has been assessed in several open label studies and retrospective reports. Some studies found that more than half of clinical responders had improvements in Clinical Global Impression scores or language and social behaviors (Chez et al. 2007; Erickson et al. 2007), although not all studies found similar effects (Owley et al. 2006; Niederhofer 2007). Open label studies with children with ASD using cholinesterase inhibitors suggest that there may be some improvement in expressive language, parent reports, and CARS scores (Niederhofer et al. 2002; Chez et al. 2004; Nicolson et al. 2006).

Many of these early clinical trials were based on hypotheses generated from mouse models. Of particular interest is Rubenstein's proposed excitatory inhibitory imbalance, which arose from electrophysiological assays in mutant mouse models (Rubenstein 2010). Both forward translation, to discover new pharmacological targets using mouse models, and back translation, to test compounds in mutant mouse models of ASD that are used off-label or have moved into clinical trials, are described below and in Table 1.

Drugs that increase GABAergic inhibition have been tested in several mouse models of autism. Using *Fmr1* mice, in which mGluR5 expression and AMPA receptors are elevated and dendritic spines are abnormal, r-baclofen corrected basal protein synthesis, reduced AMPA receptor internalization and increased spine density in *Fmr1* KO mice (Henderson et al. 2012). In the few studies that evaluated classical benzodiazepines, reduction in repetitive behaviors was reported in BTBR mice treated with clonazepam (Han et al. 2014), which also showed efficacy in social and cognitive deficits in *Scn1* heterozygous mice, a mouse model of Dravet's syndrome that exhibits ASD symptoms (Han et al. 2014). Further, acute intraperitoneal administration of r-baclofen reduced repetitive self-grooming and improved sociability in BTBR mice, and reduced stereotyped vertical jumping in C58 mice (Silverman et al. 2015).

Another strategy to reduce excitatory neurotransmission is to inhibit mGluR receptors with negative allosteric modulators. The mGluR antagonist MPEP was evaluated in the BTBR mouse model. Acute MPEP treatment reduced repetitive behaviors, including self-grooming and marble burying (Silverman et al. 2010a), and improved cognition in BTBR (Seese et al. 2014), and demonstrated anti-epileptic effects in *Fmr1* mice (Yan et al. 2005b). The mGluR5 receptor inverse agonist CTEP showed efficacy in ameliorating cognitive deficits, signaling abnormalities, and dendritic spine deficits in the *Fmr1* KO mouse (Michalon et al. 2012). The mGluR5 negative allosteric modulator GRN-529 rescued social deficits and repetitive self-grooming in BTBR mice and reduced stereotyped jumping in C58 mice (Silverman et al. 2012).

A large number of novel pharmacological targets are being tested in mouse models. Table 1 provides a partial summary of compounds tested in various mouse models. Some of these strategies have been evaluated in clinical investigations. Others may be under consideration. Well-replicated results with a compound that reverses autism-relevant phenotypes, both behavioral and biological, in multiple animal models, may contribute to decisions about pursuing a clinical trial for ASD.

5 Conclusions

The summary above and in Table 1 provides descriptions of behavioral assays relevant to the symptoms of autism, representative results of behavioral phenotypes in many rodent models, and drug treatment outcomes in several mouse models of autism. Initial hypotheses for pharmacological targets derived from animal studies that documented (1) elevated excitatory neurotransmission or excess mGluR5 receptors, (2) reduced GABAergic inhibitory physiology, circuitry, or interneurons in genetic mouse models of autism, along with (3) oxytocin modulation of social behaviors and growth factors that mediate brain development. Preclinical findings of improvements by drug treatments in mouse models of fragile X and autism have led to a small number of clinical trials. Unfortunately, the Arbaclofen trial by Seaside Therapeutics did not detect significant improvement in its primary outcome measures, and the mGluR5 antagonist trial by Roche was terminated due to lack of initial efficacy. Central questions at present include (a) whether the animal results did not incorporate sufficient predictive validity and (b) whether the clinical trials were not

optimally designed in terms of dose, age, treatment regimen, patient population, or outcome measures.

Many concerns have been raised about the predictive usefulness of results from animal models in the discovery of treatments for neuropsychiatric disorders (Markou et al. 2009; Belzung 2014). The autism field is similarly facing this dilemma. Our view is that animal studies must incorporate a high level of validity and reproducibility. Assays in rodents can be designed to maximize face validity, for maximal analogy to the behavioral and biological symptoms of autism. However, results from animal studies need to be interpreted cautiously, without exaggeration or hyperbole about relevance to the diagnostic symptoms.

Requirements for replication of positive results in two cohorts of mice would greatly increase the strength of findings. Preclinical drug studies may be most predictive when dose–response relationships have been explicated, acute and chronic treatment regimens have been tested, and clinically relevant routes of administration have been used in two or more species. These expectations represent a great deal more effort than is often invested in early preclinical studies with animal models. More complete preclinical data may be needed to provide the confidence needed to move forward into a clinical trial.

In the autism field, where no pharmacological interventions have definitively improved the core diagnostic symptoms of social interaction and communication deficits and repetitive behaviors, early failures are to be expected. Without a gold standard therapeutic, mouse models cannot be tested a priori for predictive validity. The process will be iterative.

Pharmacological target discovery is benefitting from mouse models with mutations in synaptic genes and signaling pathways identified in individuals with autism, especially in cases where the gene codes for a protein in a biological pathway which is susceptible to pharmacological intervention with available compounds. Back translation, to test compounds that are being used clinically for phenotypic reversal in animals, will help to establish whether a mutant rodent model is sufficiently predictive. The current trend for autism symposia and consortia to mix clinical and basic researchers working on pharmacological interventions is encouraging, to promote this iterative discovery process.

One major hurdle is the need for simple, real-life outcome measures of appropriate social interaction, social communication, and repetitive behaviors to use as discrete endpoints for human drug trials. Gold standard instruments for the diagnostic assessment of ASD are complex and expensive, limiting their usefulness for large-scale multi-site clinical trials of new medications. Simplified, shortened rating scales are in use and under development.

Another major hurdle is the behavioral heterogeneity which characterizes ASD, which presents a huge challenge for both clinical trials and preclinical animal models. One strategy would be to stratify the ASD population based on behavioral subgroups with specific associated symptoms, e.g. seizures, aggression, anxiety, repetitive behaviors, language skills, or IQ. Another strategy is to employ proposed biomarkers, e.g., EEG gamma activity (Bosl et al. 2011; Rojas and Wilson 2014), or delayed auditory responses (Edgar et al. 2014). Parsing ASD symptoms into more tractable endophenotypes would further allow the use of animal models to illuminate genetic underpinnings and relevant molecular pathways. Both behavioral and biomarker subcategorization of the ASD behavioral spectrum would be

valuable for preclinical drug discovery, to provide sufficiently robust cross-species biological phenotypes to complement behavioral phenotypes and permit rigorous preclinical evaluation of pharmacological interventions.

In conclusion, we return to our initial discussion of construct, face, and predictive validity in animal models. Collaboration of clinical and basic science researchers will be required at each level. Progress in the refinement of construct validity will require both clinical observation and genetics research to hasten the identification of strong risk genes for ASD and endophenotypes with relevance to its symptoms. To improve the face validity of animal models, basic scientists need to discuss the meaning of species-typical behaviors in rodents and non-human primates with clinical scientists working with individuals with ASD. In this way, there will be better assurance that the behaviors selected and assessed in animal models are relevant to humans with ASD. At the level of predictive validity, the first step will be the discovery of hypothesis-driven compounds that improve endophenotypes in both rodents and humans, particularly through the use of simpler, more real-life single outcome measures of appropriate social interaction and repetitive behaviors. While effective medical treatments for autism are greatly needed, the knowledge base about the most relevant pharmacological targets is currently at an early stage. Appropriate choices of animal model constructs, assays with strong face validity, and rigorous analysis of drug effects will contribute to the maturation of therapeutic development.

Acknowledgments

This work was supported by the MIND Institute Autism Research Training Program MH0073124 (TK), Autism Speaks Targeted Award #8703 (JC, JS) NINDS 1R01NS085709 (JC, PL), the MIND Institute Intellectual and Developmental Disabilities Research Center 1U54HD079125, and NIMH 1R01 MH103284 (MS).

References

- Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. *Nat Rev Genet.* 2008; 9:341–355. [PubMed: 18414403]
- Adise S, Saliu A, Maldonado N, Khatri V, Cardoso L, Rodriguez-Contreras A. Effect of maternal care on hearing onset induced by developmental changes in the auditory periphery. *J Neurosci.* 2014; 34:4528–4533. [PubMed: 24671998]
- Adler BA, Wink LK, Early M, Shaffer R, Minshawi N, McDougle CJ, Erickson CA. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. *Autism.* 2015; 19:102–106. [PubMed: 24571823]
- Ahern TH, Modi ME, Burkett JP, Young LJ. Evaluation of two automated metrics for analyzing partner preference tests. *J Neurosci Methods.* 2009; 182:180–188. [PubMed: 19539647]
- Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, Bomar JM, Sebat J, Wigler M, Martin CL, Ledbetter DH, Nelson SF, Cantor RM, Geschwind DH. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. *Am J Hum Genet.* 2008; 82:150–159. [PubMed: 18179893]
- Amodeo DA, Jones JH, Sweeney JA, Ragozzino ME. Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors. *Behav Brain Res.* 2012; 227:64–72. [PubMed: 22056750]
- Amodeo DA, Jones JH, Sweeney JA, Ragozzino ME. Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T+ tf/J mice. *Autism Res.* 2014a; 7:555–567. [PubMed: 24894823]
- Amodeo DA, Yi J, Sweeney JA, Ragozzino ME. Oxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice. *Front Synaptic Neurosci.* 2014b; 6:17. [PubMed: 25165445]

- Aoki Y, Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Takao H, Kawakubo Y, Kasai K, Yamasue H. Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial. *Mol Psychiatry*. 2014a; 20(4):447–453. [PubMed: 25070538]
- Aoki Y, Yahata N, Watanabe T, Takano Y, Kawakubo Y, Kuwabara H, Iwashiro N, Natsubori T, Inoue H, Suga M, Takao H, Sasaki H, Gonoï W, Kunimatsu A, Kasai K, Yamasue H. Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. *Brain*. 2014b; 137:3073–3086. [PubMed: 25149412]
- Arakawa H, Arakawa K, Blanchard DC, Blanchard RJ. A new test paradigm for social recognition evidenced by urinary scent marking behavior in C57BL/6J mice. *Behav Brain Res*. 2008; 190:97–104. [PubMed: 18359521]
- Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, Ikeda M, Rea A, Guy M, Lin S, Cook EH, Chakravarti A. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. *Am J Hum Genet*. 2008; 82:160–164. [PubMed: 18179894]
- Arnold LE, Aman MG, Hollway J, Hurt E, Bates B, Li X, Farmer C, Anand R, Thompson S, Ramadan Y, Williams C. Placebo-controlled pilot trial of mecamlamine for treatment of autism spectrum disorders. *J Child Adolesc Psychopharmacol*. 2012; 22:198–205. [PubMed: 22537359]
- Association AP. Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing; Washington, DC: 2013.
- Bachevalier J. Medial temporal lobe structures and autism: a review of clinical and experimental findings. *Neuropsychologia*. 1994; 32:627–648. [PubMed: 8084420]
- Bachevalier J, Malkova L, Mishkin M. Effects of selective neonatal temporal lobe lesions on socioemotional behavior in infant rhesus monkeys (*Macaca mulatta*). *Behav Neurosci*. 2001; 115:545–559. [PubMed: 11439445]
- Baker KB, Wray SP, Ritter R, Mason S, Lanthorn TH, Savelieva KV. Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. *Genes, Brain, Behav*. 2010; 9:562–574. [PubMed: 20398059]
- Bakkaloglu B, O'Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM, Chawarska K, Klin A, Ercan-Sencicek AG, Stillman AA, Tanriover G, Abrahams BS, Duvall JA, Robbins EM, Geschwind DH, Biederer T, Gunel M, Lifton RP, State MW. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. *Am J Hum Genet*. 2008; 82:165–173. [PubMed: 18179895]
- Bales KL, Carter CS. Developmental exposure to oxytocin facilitates partner preferences in male prairie voles (*Microtus ochrogaster*). *Behav Neurosci*. 2003a; 117:854–859. [PubMed: 12931969]
- Bales KL, Carter CS. Sex differences and developmental effects of oxytocin on aggression and social behavior in prairie voles (*Microtus ochrogaster*). *Horm Behav*. 2003b; 44:178–184. [PubMed: 14609540]
- Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, Yun CR, Solomon M, Jacob S, Mendoza SP. Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. *Biol Psychiatry*. 2013; 74:180–188. [PubMed: 23079235]
- Bales KL, Solomon M, Jacob S, Crawley JN, Silverman JL, Larke RH, Sahagun E, Puhger KR, Pride MC, Mendoza SP. Long-term exposure to intranasal oxytocin in a mouse autism model. *Transl Psychiatry*. 2014; 4:e480. [PubMed: 25386957]
- Bambini-Junior, V.; Baronio, D.; MacKenzie, J.; Zanatta, G.; Riesgo, R.; Gottfried, C. Prenatal exposure to valproate in animals and autism. In: Patel, VB., et al., editors. *Comprehensive guide to autism*. Springer; New York: 2014. p. 1779-1793.
- Bartko SJ, Romberg C, White B, Wess J, Bussey TJ, Saksida LM. Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. *Neuropharmacology*. 2011; 61:1366–1378. [PubMed: 21903112]
- Bartz JA, Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. *Prog Brain Res*. 2008; 170:451–462. [PubMed: 18655901]
- Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN. Oxytocin selectively improves empathic accuracy. *Psychol Sci*. 2010; 21:1426–1428. [PubMed: 20855907]

- Baudouin SJ, Gaudias J, Gerharz S, Hatstatt L, Zhou K, Punnakal P, Tanaka KF, Spooren W, Hen R, De Zeeuw CI, Vogt K, Scheiffele P. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. *Science*. 2012; 338:128–132. [PubMed: 22983708]
- Bauman MD, Iosif AM, Ashwood P, Braunschweig D, Lee A, Schumann CM, Van de Water J, Amaral DG. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. *Transl Psychiatry*. 2013; 3:e278. [PubMed: 23838889]
- Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. *Biol Psychiatry*. 2014; 75:332–341. [PubMed: 24011823]
- Belzung C. Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects? *Neuropsychopharmacology*. 2014; 39:1041–1051. [PubMed: 24345817]
- Berry-Kravis E, Krause SE, Block SS, Guter S, Wu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. *J Child Adolesc Psychopharmacol*. 2006; 16:525–540. [PubMed: 17069542]
- Berry-Kravis EM, Hessler D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Sci Transl Med*. 2012; 4:152ra127.
- Bielsky IF, Young LJ. Oxytocin, vasopressin, and social recognition in mammals. *Peptides*. 2004; 25:1565–1574. [PubMed: 15374658]
- Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set shifting in the rat. *J Neurosci*. 2000; 20:4320–4324. [PubMed: 10818167]
- Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebowitz D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2013; 381:817–824. [PubMed: 23312829]
- Blanchard DC, Spencer RL, Weiss SM, Blanchard RJ, McEwen B, Sakai RR. Visible burrow system as a model of chronic social stress: behavioral and neuroendocrine correlates. *Psychoneuroendocrinology*. 1995; 20:117–134. [PubMed: 7899533]
- Blanchard RJ, Dulloog L, Markham C, Nishimura O, Nikulina Compton J, Jun A, Han C, Blanchard DC. Sexual and aggressive interactions in a visible burrow system with provisioned burrows. *Physiol Behav*. 2001; 72:245–254. [PubMed: 11240003]
- Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. *Pediatric Health*. 2010; 4:375–381. [PubMed: 21359119]
- Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, Bolliger MF, Sudhof TC, Powell CM. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. *J Neurosci*. 2010; 30:2115–2129. [PubMed: 20147539]
- Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. *Behav Brain Res*. 2007; 176:21–26. [PubMed: 17097158]
- Bortolato M, Godar SC, Alzghoul L, Zhang J, Darling RD, Simpson KL, Bini V, Chen K, Wellman CL, Lin RC, Shih JC. Monoamine oxidase A and A/B knockout mice display autistic-like features. *Int J Neuropsychopharmacol*. 2013; 16:869–888. [PubMed: 22850464]
- Bosl W, Tierney A, Tager-Flusberg H, Nelson C. EEG complexity as a biomarker for autism spectrum disorder risk. *BMC Med*. 2011; 9:18. [PubMed: 21342500]
- Bouchard PR, Lynch CB. Burrowing behavior in wild house mice: variation within and between populations. *Behav Genet*. 1989; 19:447–456. [PubMed: 2757595]
- Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, Kajiwar Y, Yang M, Katz AM, Scattoni ML, Harris MJ, Saxena R, Silverman JL, Crawley JN, Zhou Q, Hof PR, Buxbaum

- JD. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. *Mol Autism*. 2010; 1:15. [PubMed: 21167025]
- Bozdagi O, Tavassoli T, Buxbaum JD. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. *Mol Autism*. 2013; 4:9. [PubMed: 23621888]
- Braunschweig D, Krakowiak P, Duncanson P, Boyce R, Hansen RL, Ashwood P, Hertz-Picciotto I, Pessah IN, Van de Water J. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. *Transl Psychiatry*. 2013; 3:e277. [PubMed: 23838888]
- Brielmaier J, Matteson PG, Silverman JL, Senerth JM, Kelly S, Genestine M, Millonig JH, DiCicco-Bloom E, Crawley JN. Autism-relevant social abnormalities and cognitive deficits in engrailed-2 knockout mice. *PLoS ONE*. 2012; 7:e40914. [PubMed: 22829897]
- Brodkin ES. BALB/c mice: low sociability and other phenotypes that may be relevant to autism. *Behav Brain Res*. 2007; 176:53–65. [PubMed: 16890300]
- Brodkin ES, Hagemann A, Nemetski SM, Silver LM. Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice. *Brain Res*. 2004; 1002:151–157. [PubMed: 14988045]
- Bromley RL, Mawer G, Clayton-Smith J, Baker GA, Liverpool and Manchester Neurodevelopment Group. Autism spectrum disorders following in utero exposure to antiepileptic drugs. *Neurology*. 2008; 71:1923–1924. [PubMed: 19047565]
- Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C, Cartwright C, Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. *Int J Neuropsychopharmacol*. 2001; 4:119–125. [PubMed: 11466160]
- Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, Thurm A, Sato S, Swedo S. An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. *J Child Adolesc Psychopharmacol*. 2011; 21:353–357. [PubMed: 21851192]
- Burket JA, Benson AD, Tang AH, Deutsch SI. D-Cycloserine improves sociability in the BTBR T+^{Itpr3tf}/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling. *Brain Res Bull*. 2013; 96:62–70. [PubMed: 23685206]
- Burket JA, Benson AD, Tang AH, Deutsch SI. Rapamycin improves sociability in the BTBR T(+)^{Itpr3(tf)}/J mouse model of autism spectrum disorders. *Brain Res Bull*. 2014; 100:70–75. [PubMed: 24295733]
- Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, Perez-Samartin A, Matute C, de la Torre R, Dierssen M, Maldonado R, Ozaita A. Targeting the endocannabinoid system in the treatment of fragile X syndrome. *Nat Med*. 2013; 19:603–607. [PubMed: 23542787]
- Byatt S, Nyby J. Hormonal regulation of chemosignals of female mice that elicit ultrasonic vocalizations from males. *Horm Behav*. 1986; 20:60–72. [PubMed: 3957260]
- Carter CS, Boone EM, Pournajafi-Nazarloo H, Bales KL. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. *Dev Neurosci*. 2009; 31:332–341. [PubMed: 19546570]
- Carter CS, DeVries AC, Getz LL. Physiological substrates of mammalian monogamy: the prairie vole model. *Neurosci Biobehav Rev*. 1995; 19:303–314. [PubMed: 7630584]
- Carter CS, Getz LL. Monogamy and the prairie vole. *Sci Am*. 1993; 268:100–106. [PubMed: 8516669]
- Carter CS, Williams JR, Witt DM, Insel TR. Oxytocin and social bonding. *Ann N Y Acad Sci*. 1992; 652:204–211. [PubMed: 1626829]
- Chabout J, Serreau P, Ey E, Bellier L, Aubin T, Bourgeron T, Granon S. Adult male mice emit context-specific ultrasonic vocalizations that are modulated by prior isolation or group rearing environment. *PLoS ONE*. 2012; 7:e29401. [PubMed: 22238608]
- Chadman KK. Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism. *Pharmacol Biochem Behav*. 2011; 97:586–594. [PubMed: 20863848]
- Chantiluke K, Barrett N, Giampietro V, Brammer M, Simmons A, Murphy DG, Rubia K. Inverse effect of fluoxetine on medial prefrontal cortex activation during reward reversal in ADHD and autism. *Cereb Cortex*. 2014a

- Chantiluke K, Barrett N, Giampietro V, Santosh P, Brammer M, Simmons A, Murphy DG, Rubia K. Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD. *Psychopharmacology*. 2014b; 232(12):2071–2082. [PubMed: 25533997]
- Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. *Ann Pharmacother*. 2006; 40:909–916. [PubMed: 16684811]
- Cheh MA, Millonig JH, Roselli LM, Ming X, Jacobsen E, Kamdar S, Wagner GC. En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. *Brain Res*. 2006; 1116:166–176. [PubMed: 16935268]
- Chen L, Toth M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. *Neuroscience*. 2001; 103:1043–1050. [PubMed: 11301211]
- Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. *J Child Neurol*. 2004; 19:165–169. [PubMed: 15119476]
- Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. *J Child Neurol*. 2007; 22:574–579. [PubMed: 17690064]
- Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*. 2013; 309:1696–1703. [PubMed: 23613074]
- Christian SL, Brune CW, Sudi J, Kumar RA, Liu S, Karamohamed S, Badner JA, Matsui S, Conroy J, McQuaid D, Gergel J, Hatchwell E, Gilliam TC, Gershon ES, Nowak NJ, Dobyns WB, Cook EH Jr. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. *Biol Psychiatry*. 2008; 63:1111–1117. [PubMed: 18374305]
- Clipperton-Allen AE, Page DT. Pten haploinsufficient mice show broad brain overgrowth but selective impairments in autism-relevant behavioral tests. *Hum Mol Genet*. 2014; 23:3490–3505. [PubMed: 24497577]
- Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P, Friend KL, Baker C, Buono S, Vissers LE, Schuurs-Hoeijmakers JH, Hoischen A, Pfundt R, Krumm N, Carvill GL, Li D, Amaral D, Brown N, Lockhart PJ, Scheffer IE, Alberti A, Shaw M, Pettinato R, Tervo R, de Leeuw N, Reijnders MR, Torchia BS, Peeters H, O’Roak BJ, Fichera M, Hehir-Kwa JY, Shendure J, Mefford HC, Haan E, Gecz J, de Vries BB, Romano C, Eichler EE. Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet*. 2014; 46:1063–1071. [PubMed: 25217958]
- Crawley JN. Exploratory behavior models of anxiety in mice. *Neurosci Biobehav Rev*. 1985; 9:37–44. [PubMed: 2858080]
- Crawley JN. Designing mouse behavioral tasks relevant to autistic-like behaviors. *Ment Retard Dev Disabil Res Rev*. 2004; 10:248–258. [PubMed: 15666335]
- Crawley JN. Translational animal models of autism and neurodevelopmental disorders. *Dialogues Clin Neurosci*. 2012; 14:293–305. [PubMed: 23226954]
- Cryan JF, Sweeney FF. The age of anxiety: role of animal models of anxiolytic action in drug discovery. *Br J Pharmacol*. 2011; 164:1129–1161. [PubMed: 21545412]
- D’Amato FR, Moles A. Ultrasonic vocalizations as an index of social memory in female mice. *Behav Neurosci*. 2001; 115:834–840. [PubMed: 11508722]
- D’Amato FR, Scalera E, Sarli C, Moles A. Pups call, mothers rush: does maternal responsiveness affect the amount of ultrasonic vocalizations in mouse pups? *Behav Genet*. 2005; 35:103–112. [PubMed: 15674537]
- D’Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP. Mildly impaired water maze performance in male *Fmr1* knockout mice. *Neuroscience*. 1997; 76:367–376. [PubMed: 9015322]
- De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, Singh T, Klei L, Kosmicki J, Shih-Chen F, Aleksic B, Biscaldi M, Bolton PF, Brownfeld JM, Cai J, Campbell NG, Carracedo A, Chahrour MH, Chiocchetti AG, Coon H, Crawford EL, Curran SR, Dawson G, Duketis E, Fernandez BA, Gallagher L, Geller E, Guter SJ, Hill RS, Ionita-Laza J, Jimenez Gonzalez P, Kilpinen H, Klauck SM, Klevzon A, Lee I, Lei I, Lei J, Lehtimäki T,

Lin CF, Ma'ayan A, Marshall CR, McInnes AL, Neale B, Owen MJ, Ozaki N, Parellada M, Parr JR, Purcell S, Puura K, Rajagopalan D, Rehnstrom K, Reichenberg A, Sabo A, Sachse M, Sanders SJ, Schafer C, Schulte-Ruther M, Skuse D, Stevens C, Szatmari P, Tammimies K, Valladares O, Voran A, Li-San W, Weiss LA, Willsey AJ, Yu TW, Yuen RK, Cook EH, Freitag CM, Gill M, Hultman CM, Lehner T, Palotie A, Schellenberg GD, Sklar P, State MW, Sutcliffe JS, Walsh CA, Scherer SW, Zwick ME, Barrett JC, Cutler DJ, Roeder K, Devlin B, Daly MJ, Buxbaum JD. Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature*. 2014; 515:209–215. [PubMed: 25363760]

- de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in *Fmr1* KO mice. *Neurobiol Dis*. 2008; 31:127–132. [PubMed: 18571098]
- Del'Guidice T, Lemay F, Lemasson M, Levasseur-Moreau J, Manta S, Etievant A, Escoffier G, Dore FY, Roman FS, Beaulieu JM. Stimulation of 5-HT_{2C} receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation. *Neuropsychopharmacology*. 2014; 39:1125–1134. [PubMed: 24196946]
- DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, Faselow MS, Delgado-Escueta A, Ellison GD, Olsen RW. Mice lacking the beta3 subunit of the GABA_A receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. *J Neurosci*. 1998; 18:8505–8514. [PubMed: 9763493]
- DeLorey TM, Sahbaie P, Hashemi E, Homanics GE, Clark JD. *Gabrb3* gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. *Behav Brain Res*. 2008; 187:207–220. [PubMed: 17983671]
- DeLorey TM, Sahbaie P, Hashemi E, Li WW, Salehi A, Clark DJ. Somatosensory and sensorimotor consequences associated with the heterozygous disruption of the autism candidate gene, *Gabrb3*. *Behav Brain Res*. 2011; 216:36–45. [PubMed: 20699105]
- Desousa A. An open-label trial of risperidone and fluoxetine in children with autistic disorder. *Indian J Psychol Med*. 2010; 32:17–21. [PubMed: 21799554]
- Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev*. 2012; 22:229–237. [PubMed: 22463983]
- Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Ankarsater H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Roge B, Heron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet*. 2007; 39:25–27. [PubMed: 17173049]
- Ecker C, Spooren W, Murphy D. Developing new pharmacotherapies for autism. *J Intern Med*. 2013; 274:308–320. [PubMed: 23865950]
- Edgar JC, Lanza MR, Daina AB, Monroe JF, Khan SY, Blaskey L, Cannon KM, Jenkins J 3rd, Qasmieh S, Levy SE, Roberts TP. Missing and delayed auditory responses in young and older children with autism spectrum disorders. *Front Hum Neurosci*. 2014; 8:417. [PubMed: 24936181]
- Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2[±] mouse model of tuberous sclerosis. *Nat Med*. 2008; 14:843–848. [PubMed: 18568033]
- Ehret G. Infant rodent ultrasounds—a gate to the understanding of sound communication. *Behav Genet*. 2005; 35:19–29. [PubMed: 15674530]
- El-Kordi A, Winkler D, Hammerschmidt K, Kastner A, Krueger D, Ronnenberg A, Ritter C, Jatho J, Radyushkin K, Bourgeron T, Fischer J, Brose N, Ehrenreich H. Development of an autism severity score for mice using *Nlgn4* null mutants as a construct-valid model of heritable monogenic autism. *Behav Brain Res*. 2013; 251:41–49. [PubMed: 23183221]
- Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C, Yasamy MT, Fombonne E. Global prevalence of autism and other pervasive developmental disorders. *Autism Res*. 2012; 5:160–179. [PubMed: 22495912]
- Engineer CT, Centanni TM, Im KW, Rahebi KC, Buell EP, Kilgard MP. Degraded speech sound processing in a rat model of fragile X syndrome. *Brain Res*. 2014; 1564:72–84. [PubMed: 24713347]

- Erickson CA, Early M, Stigler KA, Wink LK, Mullett JE, McDougle CJ. An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. *J Child Adolesc Psychopharmacol*. 2011a; 21:565–569. [PubMed: 22136091]
- Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. *J Autism Dev Disord*. 2010; 40:1412–1416. [PubMed: 20213249]
- Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. *Psychopharmacology*. 2007; 191:141–147. [PubMed: 17016714]
- Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. *Psychopharmacology*. 2011b; 216:85–90. [PubMed: 21318565]
- Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. *J Autism Dev Disord*. 2014a; 44:958–964. [PubMed: 24272415]
- Erickson CA, Wink LK, Early MC, Stieglmeyer E, Mathieu-Frasier L, Patrick V, McDougle CJ. Brief report: pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. *J Autism Dev Disord*. 2014b; 44:981–987. [PubMed: 24052275]
- Erickson CA, Wink LK, Ray B, Early MC, Stieglmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. *Psychopharmacology*. 2013; 228:75–84. [PubMed: 23436129]
- Esclassan F, Francois J, Phillips KG, Loomis S, Gilmour G. Phenotypic characterization of nonsocial behavioral impairment in neurexin 1 α knockout rats. *Epub* 2014 Nov 24. *Behav Neurosci*. 2015; 129(1):74–85. DOI: 10.1037/bne0000024 [PubMed: 25420124]
- Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1 α deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. *Proc Natl Acad Sci*. 2009; 106:17998–18003. [PubMed: 19822762]
- Ey E, Leblond CS, Bourgeron T. Behavioral profiles of mouse models for autism spectrum disorders. *Autism Res*. 2011; 4:5–16. [PubMed: 21328568]
- Ey E, Yang M, Katz AM, Woldeyohannes L, Silverman JL, Leblond CS, Faure P, Torquet N, Le Sourd AM, Bourgeron T, Crawley JN. Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4. *Genes, Brain, Behav*. 2012; 11(8): 928–841. [PubMed: 22989184]
- Fairless AH, Katz JM, Vijayvargiya N, Dow HC, Kreibich AS, Berrettini WH, Abel T, Brodtkin ES. Development of home cage social behaviors in BALB/cJ vs. C57BL/6J mice. *Behav Brain Res*. 2013; 237:338–347. [PubMed: 22982070]
- Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. *J Autism Dev Disord*. 1998; 28:303–307. [PubMed: 9711486]
- Ferguson JN, Aldag JM, Insel TR, Young LJ. Oxytocin in the medial amygdala is essential for social recognition in the mouse. *J Neurosci*. 2001; 21:8278–8285. [PubMed: 11588199]
- Fernandez BA, Roberts W, Chung B, Weksberg R, Meyn S, Szatmari P, Joseph-George AM, Mackay S, Whitten K, Noble B, Vardy C, Crosbie V, Luscombe S, Tucker E, Turner L, Marshall CR, Scherer SW. Phenotypic spectrum associated with de novo and inherited deletions and duplications at 16p11.2 in individuals ascertained for diagnosis of autism spectrum disorder. *J Med Genet*. 2010; 47:195–203. [PubMed: 19755429]
- Fernandez T, Morgan T, Davis N, Klin A, Morris A, Farhi A, Lifton RP, State MW. Disruption of Contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. *Am J Hum Genet*. 2008; 82:1385. [PubMed: 18551756]
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. *J Clin Psychiatry*. 2014; 75:22–30. [PubMed: 24502859]

- Finlay JM, Dunham GA, Isherwood AM, Newton CJ, Nguyen TV, Reppar PC, Snitkovski I, Paschall SA, Greene RW. Effects of prefrontal cortex and hippocampal NMDA-NR1 subunit deletion on complex cognitive and social behaviors. *Brain Res.* 2014; 1600:70–83. [PubMed: 25452020]
- Fischer J, Hammerschmidt K. Ultrasonic vocalizations in mouse models for speech and socio-cognitive disorders: insights into the evolution of vocal communication. *Genes Brain Behav.* 2011; 10:17–27. [PubMed: 20579107]
- Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebowitz D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet.* 2013; 381:125–132. [PubMed: 23158522]
- Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. *Drug Healthc Patient Saf.* 2014; 6:69–76. [PubMed: 24872724]
- Galef BG Jr. Social learning of food preferences in rodents: rapid appetitive learning. *Current protocols in neuroscience.* 2003 Chapter 8: Unit 8 5D.
- Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ. Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. *Biol Psychiatry.* 2010; 68:1100–1106. [PubMed: 21130222]
- Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T, Anderson R, Pierce RC, Jonak G, Gur RE, Carlson G, Siegel SJ. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. *Transl Psychiatry.* 2012; 2:e142. [PubMed: 22806213]
- Gandhi RM, Kogan CS, Messier C. 2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. *Front Cell Neurosci.* 2014; 8:70. [PubMed: 24701200]
- Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, Gasparini F, Oostra BA, D'Hooze R, Willemsen R. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. *Behav Brain Res.* 2013; 239:72–79. [PubMed: 23142366]
- Ghaeli P, Nikvarz N, Alaghband-Rad J, Alimadadi A, Tehrani-Doost M. Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. *Indian J Psychol Med.* 2014; 36:66–70. [PubMed: 24701014]
- Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. *Pediatr Neurol.* 2015; 52:77–81. [PubMed: 25451017]
- Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. *Physiol Rev.* 2001; 81:629–683. [PubMed: 11274341]
- Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang H, Estes A, Brune CW, Bradfield JP, Imielinski M, Frackelton EC, Reichert J, Crawford EL, Munson J, Sleiman PM, Chiavacci R, Annaiah K, Thomas K, Hou C, Glaberson W, Flory J, Otieno F, Garriss M, Soorya L, Klei L, Piven J, Meyer KJ, Anagnostou E, Sakurai T, Game RM, Rudd DS, Zurawiecki D, McDougall CJ, Davis LK, Miller J, Posey DJ, Michaels S, Kolevzon A, Silverman JM, Bernier R, Levy SE, Schultz RT, Dawson G, Owley T, McMahon WM, Wassink TH, Sweeney JA, Nurnberger Jr, Coon H, Sutcliffe JS, Minshew NJ, Grant SF, Bucan M, Cook EH, Buxbaum JD, Devlin B, Schellenberg GD, Hakonarson H. Autism genome-wide copy number variation reveals ubiquitous and neuronal genes. *Nature.* 2009; 459:569–573. [PubMed: 19404257]
- Goorden SM, van Woerden GM, van der Weerd L, Cheadle JP, Elgersma Y. Cognitive deficits in Tsc1 ± mice in the absence of cerebral lesions and seizures. *Ann Neurology.* 2007; 62:648–655.
- Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, Zagoory-Sharon O, Leckman JF, Feldman R, Pelphrey KA. Oxytocin enhances brain function in children with autism. *Proc Natl Acad Sci.* 2013; 110:20953–20958. [PubMed: 24297883]
- Gould GG, Hensler JG, Burke TF, Benno RH, Onaivi ES, Daws LC. Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+ tf/J mouse social behavior. *J Neurochem.* 2011; 116:291–303. [PubMed: 21070242]

- Greco B, Manago F, Tucci V, Kao HT, Valtorta F, Benfenati F. Autism-related behavioral abnormalities in synapsin knockout mice. *Behav Brain Res*. 2013; 251:65–74. [PubMed: 23280234]
- Gross C, Hoffmann A, Bassel GJ, Berry-Kravis EM. Therapeutic strategies in Fragile X syndrome: From bench to bedside and back. *Neurother*. 2015; 12:584–608.
- Guariglia SR, Chadman KK. Water T-maze: a useful assay for determination of repetitive behaviors in mice. *J Neurosci Methods*. 2013; 220:24–29. [PubMed: 23994357]
- Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. *Biol Psychiatry*. 2010; 67:692–694. [PubMed: 19897177]
- Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. *J Child Psychol Psychiatry Allied Disciplines*. 2014; 56(4):444–452.
- Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, Miller J, Fedele A, Collins J, Smith K, Lotspeich L, Croen LA, Ozonoff S, Lajonchere C, Grether JK, Risch N. Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen Psychiatry*. 2011; 68:1095–1102. [PubMed: 21727249]
- Hamilton SM, Green JR, Veeraragavan S, Yuva L, McCoy A, Wu Y, Warren J, Little L, Ji D, Cui X, Weinstein E, Paylor R. Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders. *Behav Neurosci*. 2014; 128:103–109. [PubMed: 24773431]
- Hammerschmidt K, Radyushkin K, Ehrenreich H, Fischer J. Female mice respond to male ultrasonic ‘songs’ with approach behaviour. *Biol Lett*. 2009; 5:589–592. [PubMed: 19515648]
- Hammerschmidt K, Reisinger E, Westekemper K, Ehrenreich L, Strenze N, Fischer J. Mice do not require auditory input for the normal development of their ultrasonic vocalizations. *BMC Neurosci*. 2012; 13:40. [PubMed: 22533376]
- Han S, Tai C, Jones CJ, Scheuer T, Catterall WA. Enhancement of inhibitory neurotransmission by GABAA receptors having alpha2,3-subunits ameliorates behavioral deficits in a mouse model of autism. *Neuron*. 2014; 81:1282–1289. [PubMed: 24656250]
- Handen BL, Johnson CR, Butter EM, Lecavalier L, Scahill L, Aman MG, McDougale CJ, Arnold LE, Swiezy NB, Sukhodolsky DG, Mulick JA, White SW, Bearss K, Hollway JA, Stigler KA, Dziura J, Yu S, Sacco K, Vitiello B. Use of a direct observational measure in a trial of risperidone and parent training in children with pervasive developmental disorders. *J Dev Phys Disabil*. 2013; 25:355–371. [PubMed: 23730123]
- Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. *J Child Adolesc Psychopharmacol*. 2011; 21:43–50. [PubMed: 21309696]
- Hanson JL, Hurley LM. Female presence and estrous state influence mouse ultrasonic courtship vocalizations. *PLoS ONE*. 2012; 7:e40782. [PubMed: 22815817]
- Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. *J Child Adolesc Psychopharmacol*. 2002; 12:237–241. [PubMed: 12427297]
- Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklisch PW, Kind PC, Carpenter RL, Bear MF, Healy AM. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. *Sci Transl Med*. 2012; 4:152ra128.
- Hoffmann F, Musolf K, Penn DJ. Freezing urine reduces its efficacy for eliciting ultrasonic vocalizations from male mice. *Physiol Behav*. 2009; 96:602–605. [PubMed: 19150619]
- Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. *Biol Psychiatry*. 2007; 61:498–503. [PubMed: 16904652]
- Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. *Neuropsychopharmacology*. 2003; 28:193–198. [PubMed: 12496956]

- Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. *Neuropsychopharmacology*. 2005; 30:582–589. [PubMed: 15602505]
- Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settapani C. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. *Am J Psychiatry*. 2012; 169:292–299. [PubMed: 22193531]
- Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *J Child Adolesc Psychopharmacol*. 2006; 16:541–548. [PubMed: 17069543]
- Holy TE, Guo Z. Ultrasonic songs of male mice. *PLoS Biol*. 2005; 3:e386. [PubMed: 16248680]
- Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CE, Korpi ER, Makela R, Brilliant MH, Hagiwara N, Ferguson C, Snyder K, Olsen RW. Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. *Proc Natl Acad Sci*. 1997; 94:4143–4148. [PubMed: 9108119]
- Huang H, Michetti C, Busnelli M, Manago F, Sannino S, Scheggia D, Giancardo L, Sona D, Murino V, Chini B, Scattoni ML, Papaleo F. Chronic and acute intranasal oxytocin produce divergent social effects in mice. *Neuropsychopharmacology*. 2014; 39:1102–1114. [PubMed: 24190025]
- Winarni TI, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, Nguyen DV, Hagerman RJ. Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review. *Autism Res Treat*. 2012; 2012:104317. [PubMed: 22934167]
- Insel TR, Hill JL, Mayor RB. Rat pup ultrasonic isolation calls: possible mediation by the benzodiazepine receptor complex. *Pharmacol Biochem Behav*. 1986; 24:1263–1267. [PubMed: 2425378]
- Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, Stessman HA, Witherspoon KT, Vives L, Patterson KE, Smith JD, Paepers B, Nickerson DA, Dea J, Dong S, Gonzalez LE, Mandell JD, Mane SM, Murtha MT, Sullivan CA, Walker MF, Waqar Z, Wei L, Willsey AJ, Yamrom B, Lee YH, Grabowska E, Dalkic E, Wang Z, Marks S, Andrews P, Leotta A, Kendall J, Hakker I, Rosenbaum J, Ma B, Rodgers L, Troge J, Narzisi G, Yoon S, Schatz MC, Ye K, McCombie WR, Shendure J, Eichler EE, State MW, Wigler M. The contribution of de novo coding mutations to autism spectrum disorder. *Nature*. 2014; 515:216–221. [PubMed: 25363768]
- Ishitobi M, Kosaka H, Takahashi T, Yatuga C, Asano M, Tanaka Y, Ueno K, Okazaki R, Omori M, Hiratani M, Tomoda A, Wada Y. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study. *Clin Neuropharmacol*. 2013; 36:151–156. [PubMed: 24045605]
- Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, Giros B, Leboyer M, Gillberg C, Bourgeron T. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat Genet*. 2003; 34:27–29. [PubMed: 12669065]
- Jamain S, Radyushkin K, Hammerschmidt K, Granon S, Boretius S, Varoqueaux F, Ramanantsoa N, Gallego J, Ronnenberg A, Winter D, Frahm J, Fischer J, Bourgeron T, Ehrenreich H, Brose N. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. *Proc Natl Acad Sci*. 2008; 105:1710–1715. [PubMed: 18227507]
- Jiang YH, Ehlers MD. Modeling autism by SHANK gene mutations in mice. *Neuron*. 2013; 78:8–27. [PubMed: 23583105]
- Kaidanovich-Beilin O, Lipina T, Vukobradovic I, Roder J, Woodgett JR. Assessment of social interaction behaviors. *J Vis Exp*. 2011; 48
- Karvat G, Kimchi T. Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism. *Neuropsychopharmacology*. 2014; 39:831–840. [PubMed: 24096295]
- Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. *J Clin Psychopharmacol*. 2002; 22:455–460. [PubMed: 12352267]

- Kent JM, Hough D, Singh J, Karcher K, Pandina G. An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. *J Child Adolesc Psychopharmacol*. 2013a; 23:676–686. [PubMed: 24350813]
- Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, Singh J, Hough D. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. *J Autism Dev Disord*. 2013b; 43:1773–1783. [PubMed: 23212807]
- Kerr TM, Muller CL, Miah M, Jetter CS, Pfeiffer R, Shah C, Baganz N, Anderson GM, Crawley JN, Sutcliffe JS, Blakely RD, Veenstra-Vanderweele J. Genetic background modulates phenotypes of serotonin transporter Ala56 knock-in mice. *Mol Autism*. 2013; 1:4.doi: 10.1186/2040-2392-4-35
- Kikusui T, Nakanishi K, Nakagawa R, Nagasawa M, Mogi K, Okanoya K. Cross fostering experiments suggest that mice songs are innate. *PLoS ONE*. 2011; 6:e17721. [PubMed: 21408017]
- Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, Shen Y, Lally E, Weiss LA, Najm J, Kutsche K, Descartes M, Holt L, Braddock S, Troxell R, Kaplan L, Volkmar F, Klin A, Tsatsanis K, Harris DJ, Noens I, Pauls DL, Daly MJ, MacDonald ME, Morton CC, Quade BJ, Gusella JF. Disruption of neurexin 1 associated with autism spectrum disorder. *Am J Hum Genet*. 2008; 82:199–207. [PubMed: 18179900]
- Kim JW, Seung H, Kwon KJ, Ko MJ, Lee EJ, Oh HA, Choi CS, Kim KC, Gonzales EL, You JS, Choi DH, Lee J, Han SH, Yang SM, Cheong JH, Shin CY, Bahn GH. Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism. *PLoS ONE*. 2014a; 9:e104927. [PubMed: 25133713]
- Kim SH, Junker D, Lord C. Observation of spontaneous expressive language (OSEL): a new measure for spontaneous and expressive language of children with autism spectrum disorders and other communication disorders. *J Autism Dev Disord*. 2014b; 44:3230–3244. [PubMed: 25022249]
- Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, Cheon KA, Kim SJ, Kim YK, Lee H, Song DH, Grinker RR. Prevalence of autism spectrum disorders in a total population sample. *Am J Psychiatry*. 2011; 168:904–912. [PubMed: 21558103]
- King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L, Network SP. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. *Arch Gen Psychiatry*. 2009; 66:583–590. [PubMed: 19487623]
- Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, Gudjonsson SA, Sigurdsson A, Jonasdottir A, Wong WS, Sigurdsson G, Walters GB, Steinberg S, Helgason H, Thorleifsson G, Gudbjartsson DF, Helgason A, Magnusson OT, Thorsteinsdottir U, Stefansson K. Rate of de novo mutations and the importance of father's age to disease risk. *Nature*. 2012; 488:471–475. [PubMed: 22914163]
- Kramvis I, Mansvelder HD, Loos M, Meredith R. Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model. *Front Behav Neurosci*. 2013; 7:172. [PubMed: 24312033]
- Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. *N Engl J Med*. 2010; 363:1801–1811. [PubMed: 21047224]
- Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. *Ann Neurol*. 2013; 74:679–687. [PubMed: 23798472]
- Kudryavtseva NN. Use of the “partition” test in behavioral and pharmacological experiments. *Neurosci Behav Physiol*. 2003; 33:461–471. [PubMed: 12921177]
- Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF. Pten regulates neuronal arborization and social interaction in mice. *Neuron*. 2006; 50:377–388. [PubMed: 16675393]
- Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BC, Andres C, Barthelemy C, Moraine C, Briault S. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. *Am J Hum Genet*. 2004; 74:552–557. [PubMed: 14963808]

- Lauterborn JC, Rex CS, Kramar E, Chen LY, Pandeyarajan V, Lynch G, Gall CM. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. *J Neurosci*. 2007; 27:10685–10694. [PubMed: 17913902]
- Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. *Eur J Hum Genet EJHG*. 2008; 16:614–618. [PubMed: 18231125]
- Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K, Stevens KE, Maccaferri G, McBain CJ, Sussman DJ, Wynshaw-Boris A. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. *Cell*. 1997; 90:895–905. [PubMed: 9298901]
- Lim ET, Raychaudhuri S, Sanders SJ, Stevens C, Sabo A, MacArthur DG, Neale BM, Kirby A, Ruderfer DM, Fromer M, Lek M, Liu L, Flannick J, Ripke S, Nagaswamy U, Muzny D, Reid JG, Hawes A, Newsham I, Wu Y, Lewis L, Dinh H, Gross S, Wang LS, Lin CF, Valladares O, Gabriel SB, dePristo M, Altshuler DM, Purcell SM, State MW, Boerwinkle E, Buxbaum JD, Cook EH, Gibbs RA, Schellenberg GD, Sutcliffe JS, Devlin B, Roeder K, Daly MJ. Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. *Neuron*. 2013; 77:235–242. [PubMed: 23352160]
- Lin IF, Kashino M, Ohta H, Yamada T, Tani M, Watanabe H, Kanai C, Ohno T, Takayama Y, Iwanami A, Kato N. The effect of intranasal oxytocin versus placebo treatment on the autonomic responses to human sounds in autism: a single-blind, randomized, placebo-controlled, crossover design study. *Mol Autism*. 2014; 5:20. [PubMed: 24576333]
- Lloyd JA. Social structure and reproduction in two freely growing populations of house mice (*Mus musculus* L.). *Anim Behav*. 1975; 23:413–424.
- Long JM, LaPorte P, Paylor R, Wynshaw-Boris A. Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. *Genes Brain Behav*. 2004; 3:51–62. [PubMed: 14960015]
- Lord C, Jones RM. New strategies and findings for behavioral interventions in autism spectrum disorders. *Ann NY Acad Sci*. 2013; 1304:70–76. [PubMed: 24279894]
- Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord*. 2000; 30:205–223. [PubMed: 11055457]
- MacPherson P, McGaffigan R, Wahlsten D, Nguyen PV. Impaired fear memory, altered object memory and modified hippocampal synaptic plasticity in split-brain mice. *Brain Res*. 2008; 1210:179–188. [PubMed: 18417102]
- Macri S, Biamonte F, Romano E, Marino R, Keller F, Laviola G. Perseverative responding and neuroanatomical alterations in adult heterozygous reeler mice are mitigated by neonatal estrogen administration. *Psychoneuroendocrinology*. 2010; 35:1374–1387. [PubMed: 20452127]
- Maggio JC, Whitney G. Ultrasonic vocalizing by adult female mice (*Mus musculus*). *J Comp Psychol*. 1985; 99:420–436. [PubMed: 4075780]
- Mahrt EJ, Perkel DJ, Tong L, Rubel EW, Portfors CV. Engineered deafness reveals that mouse courtship vocalizations do not require auditory experience. *J Neurosci*. 2013; 33:5573–5583. [PubMed: 23536072]
- Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G, Chen G, Crawley JN, Manji HK. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. *Biol Psychiatry*. 2010; 67:864–871. [PubMed: 20034613]
- Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. *J Am Acad Child Adolesc Psychiatry*. 2001; 40:887–894. [PubMed: 11501687]
- Maloney A, Mick EO, Frazier J. Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders. *J Child Adolesc Psychopharmacol*. 2014; 24:357–359. [PubMed: 24828130]
- Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA, Marcus R. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. *J Child Adolesc Psychopharmacol*. 2013; 23:572–576. [PubMed: 24138011]

- Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry*. 2009; 48:1110–1119. [PubMed: 19797985]
- Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Corey-Lisle PK, Aman MG. Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. *J Child Adolesc Psychopharmacol*. 2011a; 21:229–236. [PubMed: 21663425]
- Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. *J Clin Psychiatry*. 2011b; 72:1270–1276. [PubMed: 21813076]
- Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. *Neuropsychopharmacology*. 2009; 34:74–89. [PubMed: 18830240]
- Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, Thiruvahindrapuram B, Fiebig A, Schreiber S, Friedman J, Ketelaars CE, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R, Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, Zwaigenbaum L, Roberts W, Fernandez B, Szatmari P, Scherer SW. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 2008; 82:477–488. [PubMed: 18252227]
- Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. *Brain Behav Immun*. 2008; 22:806–816. [PubMed: 18262386]
- Matson JL, Shoemaker M. Intellectual disability and its relationship to autism spectrum disorders. *Res Dev Disabil*. 2009; 30:1107–1114. [PubMed: 19604668]
- Matsunami N, Hadley D, Hensel CH, Christensen GB, Kim C, Frackelton E, Thomas K, da Silva RP, Stevens J, Baird L, Otterud B, Ho K, Varvil T, Leppert T, Lambert CG, Leppert M, Hakonarson H. Identification of rare recurrent copy number variants in high-risk autism families and their prevalence in a large ASD population. *PLoS ONE*. 2013; 8:e52239. [PubMed: 23341896]
- Mayko ZM, Roberts PD, Portfors CV. Inhibition shapes selectivity to vocalizations in the inferior colliculus of awake mice. *Front Neural Circuits*. 2012; 6:73. [PubMed: 23087616]
- McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougale CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in children with autism and serious behavioral problems. *N England J Med*. 2002; 347:314–321. [PubMed: 12151468]
- McDougale CJ, Brodtkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. *J Clin Psychopharmacol*. 1998; 18:62–66. [PubMed: 9472844]
- McDougale CJ, Epperson CN, Pelton GH, Wasyluk S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. *Arch Gen Psychiatry*. 2000; 57:794–801. [PubMed: 10920469]
- McDougale CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. *Arch Gen Psychiatry*. 1996; 53:1001–1008. [PubMed: 8911223]
- McDougale CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. *Am J Psychiatry*. 2005; 162:1142–1148. [PubMed: 15930063]
- McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN. Autism-like behavioral phenotypes in BTBR T+ tf/J mice. *Genes Brain Behav*. 2008; 7:152–163. [PubMed: 17559418]

- McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG. The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. *PLoS ONE*. 2013; 8:e62189. [PubMed: 23638000]
- Mehta MV, Gandal MJ, Siegel SJ. mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. *PLoS ONE*. 2011; 6:e26077. [PubMed: 22016815]
- Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. *J Neurosci*. 2008; 28:5422–5432. [PubMed: 18495876]
- Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. *J Neurosci*. 2007; 27:5546–5558. [PubMed: 17522300]
- Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. *Neuron*. 2012; 74:49–56. [PubMed: 22500629]
- Miczek KA, Maxson SC, Fish EW, Faccidomo S. Aggressive behavioral phenotypes in mice. *Behav Brain Res*. 2001; 125:167–181. [PubMed: 11682108]
- Miles JH. Autism spectrum disorders—a genetics review. *Genet Med*. 2011; 13:278–294. [PubMed: 21358411]
- Modi ME, Connor-Stroud F, Landgraf R, Young LJ, Parr LA. Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. *Psychoneuroendocrinology*. 2014; 45:49–57. [PubMed: 24845176]
- Modi ME, Young LJ. D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders. *Biol Psychiatry*. 2011; 70:298–304. [PubMed: 21481844]
- Modi ME, Young LJ. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. *Horm Behav*. 2012; 61:340–350. [PubMed: 22206823]
- Moles A, Kieffer BL, D'Amato FR. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. *Science*. 2004; 304:1983–1986. [PubMed: 15218152]
- Molina J, Carmona-Mora P, Chrast J, Krall PM, Canales CP, Lupski JR, Reymond A, Walz K. Abnormal social behaviors and altered gene expression rates in a mouse model for Potocki-Lupski syndrome. *Hum Mol Genet*. 2008; 17:2486–2495. [PubMed: 18469339]
- Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, Kohn M. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. *Trials*. 2014; 15:230. [PubMed: 24934401]
- Moy SS, Nadler JJ. Advances in behavioral genetics: mouse models of autism. *Mol Psychiatry*. 2008; 13:4–26. [PubMed: 17848915]
- Moy SS, Nadler JJ, Magnuson TR, Crawley JN. Mouse models of autism spectrum disorders: the challenge for behavioral genetics. *Am J Med Genet Part C, Semin Med Genet*. 2006; 142C:40–51. [PubMed: 16419099]
- Moy SS, Nadler JJ, Poe MD, Nonneman RJ, Young NB, Koller BH, Crawley JN, Duncan GE, Bodfish JW. Development of a mouse test for repetitive, restricted behaviors: relevance to autism. *Behav Brain Res*. 2008a; 188:178–194. [PubMed: 18068825]
- Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, Murphy DL, D'Ercole AJ, Crawley JN, Magnuson TR, Lauder JM. Social approach in genetically engineered mouse lines relevant to autism. *Genes Brain Behav*. 2009; 8:129–142. [PubMed: 19016890]
- Moy SS, Nadler JJ, Young NB, Nonneman RJ, Segall SK, Andrade GM, Crawley JN, Magnuson TR. Social approach and repetitive behavior in eleven inbred mouse strains. *Behav Brain Res*. 2008b; 191:118–129. [PubMed: 18440079]
- Moy SS, Nadler JJ, Young NB, Perez A, Holloway LP, Barbaro RP, Barbaro JR, Wilson LM, Threadgill DW, Lauder JM, Magnuson TR, Crawley JN. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. *Behav Brain Res*. 2007; 176:4–20. [PubMed: 16971002]

- Murdoch JD, State MW. Recent developments in the genetics of autism spectrum disorders. *Curr Opin Genet Dev.* 2013; 23:310–315. [PubMed: 23537858]
- Nadler JJ, Moy SS, Dold G, Trang D, Simmons N, Perez A, Young NB, Barbaro RP, Piven J, Magnuson TR, Crawley JN. Automated apparatus for quantitation of social approach behaviors in mice. *Genes Brain Behav.* 2004; 3:303–314. [PubMed: 15344923]
- Nakatani J, Tamada K, Hatanaka F, Ise S, Ohta H, Inoue K, Tomonaga S, Watanabe Y, Chung YJ, Banerjee R, Iwamoto K, Kato T, Okazawa M, Yamauchi K, Tanda K, Takao K, Miyakawa T, Bradley A, Takumi T. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. *Cell.* 2009; 137:1235–1246. [PubMed: 19563756]
- Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. *J Child Adolesc Psychopharmacol.* 2006; 16:621–629. [PubMed: 17069550]
- Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. *J Clin Psychopharmacol.* 2007; 27:317–318. [PubMed: 17502791]
- Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. *BMJ.* 2002; 325:1422.
- Nordenbaek C, Jorgensen M, Kyvik KO, Bilenberg N. A Danish population-based twin study on autism spectrum disorders. *Eur Child Adolesc Psychiatry.* 2014; 23:35–43. [PubMed: 23661220]
- Nyby J, Wysocki CJ, Whitney G, Dizinno G. Pheromonal regulation of male mouse ultrasonic courtship (*Mus musculus*). *Anim Behav.* 1977; 25:333–341. [PubMed: 889149]
- O’Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, Vives L, Baker C, Hiatt JB, Nickerson DA, Bernier R, Shendure J, Eichler EE. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nat Commun.* 2014; 5:5595. [PubMed: 25418537]
- Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. *J Neurosci.* 2007; 27:10912–10917. [PubMed: 17913925]
- Okabe S, Nagasawa M, Kihara T, Kato M, Harada T, Koshida N, Mogi K, Kikusui T. Pup odor and ultrasonic vocalizations synergistically stimulate maternal attention in mice. *Behav Neurosci.* 2013; 127:432–438. [PubMed: 23544596]
- Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics.* 2009; 124:1533–1540. [PubMed: 19948625]
- Owley T, Salt J, Guter S, Grieve A, Walton L, Ayuyao N, Leventhal BL, Cook EH Jr. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. *J Child Adolesc Psychopharmacol.* 2006; 16:517–524. [PubMed: 17069541]
- Page DT, Kuti OJ, Prestia C, Sur M. Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior. *Proc Natl Acad Sci.* 2009; 106:1989–1994. [PubMed: 19208814]
- Panksepp JB, Jochman KA, Kim JU, Koy JJ, Wilson ED, Chen Q, Wilson CR, Lahvis GP. Affiliative behavior, ultrasonic communication and social reward are influenced by genetic variation in adolescent mice. *PLoS ONE.* 2007; 2:e351. [PubMed: 17406675]
- Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. *Neuroscience.* 1999; 94:185–192. [PubMed: 10613508]
- Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V, Horvath S, Geschwind DH. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. *Cell.* 2013; 155:1008–1021. [PubMed: 24267887]
- Parr LA, Modi M, Siebert E, Young LJ. Intranasal oxytocin selectively attenuates rhesus monkeys’ attention to negative facial expressions. *Psychoneuroendocrinology.* 2013; 38:1748–1756. [PubMed: 23490074]
- Patterson PH. Modeling autistic features in animals. *Pediatr Res.* 2011; 69:34R–40R. [PubMed: 20940665]

- Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, Lascola CD, Fu Z, Feng G. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature*. 2011; 472:437–442. [PubMed: 21423165]
- Penagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, Sonnenblick LI, Gruver R, Almajano J, Bragin A, Golshani P, Trachtenberg JT, Peles E, Geschwind DH. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell*. 2011; 147:235–246. [PubMed: 21962519]
- Perou R, Bitsko RH, Blumberg SJ, Pastor P, Ghandour RM, Gfroerer JC, Hedden SL, Crosby AE, Visser SN, Schieve LA, Parks SE, Hall JE, Brody D, Simile CM, Thompson WW, Baio J, Avenevoli S, Kogan MD, Huang LN. Mental health surveillance among children—United States, 2005–2011. *MMWR Surveill Summ*. 2013; 62(Suppl 2):1–35.
- Pini G, Scusa MF, Benincasa A, Bottiglioni I, Congiu L, Vadhatpour C, Romanelli AM, Gemo I, Puccetti C, McNamara R, O’Leary S, Corvin A, Gill M, Tropea D. Repeated insulin-like growth factor 1 treatment in a patient with rett syndrome: a single case study. *Front Pediatr*. 2014; 2:52. [PubMed: 24918098]
- Pini G, Scusa MF, Congiu L, Benincasa A, Morescalchi P, Bottiglioni I, Di Marco P, Borelli P, Bonuccelli U, Della-Chiesa A, Prina-Mello A, Tropea D. IGF1 as a potential treatment for rett syndrome: safety assessment in six rett patients. *Autism Res Treat*. 2012; 2012:679801. [PubMed: 22934177]
- Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, Thiruvahindrapuram B, Xu X, Ziman R, Wang Z, Vorstman JA, Thompson A, Regan R, Pilorge M, Pellecchia G, Pagnamenta AT, Oliveira B, Marshall CR, Magalhaes TR, Lowe JK, Howe JL, Griswold AJ, Gilbert J, Duketis E, Dombroski BA, De Jonge MV, Cuccaro M, Crawford EL, Correia CT, Conroy J, Conceicao IC, Chiochetti AG, Casey JP, Cai G, Cabrol C, Bolshakova N, Bacchelli E, Anney R, Gallinger S, Cotterchio M, Casey G, Zwaigenbaum L, Wittemeyer K, Wing K, Wallace S, van Engeland H, Tryfon A, Thomson S, Soorya L, Roge B, Roberts W, Poustka F, Moug S, Minshew N, McInnes LA, McGrew SG, Lord C, Leboyer M, Le Couteur AS, Kolevzon A, Jimenez Gonzalez P, Jacob S, Holt R, Guter S, Green J, Green A, Gillberg C, Fernandez BA, Duque F, Delorme R, Dawson G, Chaste P, Cafe C, Brennan S, Bourgeron T, Bolton PF, Bolte S, Bernier R, Baird G, Bailey AJ, Anagnostou E, Almeida J, Wijsman EM, Veland VJ, Vicente AM, Schellenberg GD, Pericak-Vance M, Paterson AD, Parr JR, Oliveira G, Nurnberger JI, Monaco AP, Maestrini E, Klauck SM, Hakonarson H, Haines JL, Geschwind DH, Freitag CM, Folstein SE, Ennis S, Coon H, Battaglia A, Szatmari P, Sutcliffe JS, Hallmayer J, Gill M, Cook EH, Buxbaum JD, Devlin B, Gallagher L, Betancur C, Scherer SW. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet*. 2014; 94:677–694. [PubMed: 24768552]
- Pobbe RL, Defensor EB, Pearson BL, Bolivar VJ, Blanchard DC, Blanchard RJ. General and social anxiety in the BTBR T+ tf/J mouse strain. *Behav Brain Res*. 2011; 216:446–451. [PubMed: 20816701]
- Pobbe RL, Pearson BL, Defensor EB, Bolivar VJ, Blanchard DC, Blanchard RJ. Expression of social behaviors of C57BL/6J versus BTBR inbred mouse strains in the visible burrow system. *Behav Brain Res*. 2010; 214:443–449. [PubMed: 20600340]
- Pomerantz SM, Nunez AA, Bean NJ. Female behavior is affected by male ultrasonic vocalizations in house mice. *Physiol Behav*. 1983; 31:91–96. [PubMed: 6685321]
- Pop AS, Levenga J, de Esch CE, Buijsen RA, Nieuwenhuizen IM, Li T, Isaacs A, Gasparini F, Oostra BA, Willemsen R. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. *Psychopharmacology*. 2014; 231:1227–1235. [PubMed: 23254376]
- Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, Bader PL, Grueter BA, Goold C, Fisher E, Clifford K, Rengarajan P, Kalikhman D, Loureiro D, Saw NL, Zhengqui Z, Miller MA, Lerch JP, Henkelman RM, Shamloo M, Malenka RC, Crawley JN, Dolmetsch RE. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. *Cell Reports*. 2014; 7:1077–1092. [PubMed: 24794428]

- Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougale CJ. A pilot study of D-cycloserine in subjects with autistic disorder. *Am J Psychiatry*. 2004; 161:2115–2117. [PubMed: 15514414]
- Potenza MN, Holmes JP, Kaner SJ, McDougale CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. *J Clin Psychopharmacol*. 1999; 19:37–44. [PubMed: 9934941]
- Poultney CS, Goldberg AP, Drapeau E, Kou Y, Harony-Nicolas H, Kajiwarra Y, De Rubeis S, Durand S, Stevens C, Rehnstrom K, Palotie A, Daly MJ, Ma'ayan A, Fromer M, Buxbaum JD. Identification of small exonic CNV from whole-exome sequence data and application to autism spectrum disorder. *Am J Hum Genet*. 2013; 93:607–619. [PubMed: 24094742]
- Prather MD, Lavenex P, Mauldin-Jourdain ML, Mason WA, Capitanio JP, Mendoza SP, Amaral DG. Increased social fear and decreased fear of objects in monkeys with neonatal amygdala lesions. *Neuroscience*. 2001; 106:653–658. [PubMed: 11682152]
- Puscian A, Leski S, Gorkiewicz T, Meyza K, Lipp HP, Knapka E. A novel automated behavioral test battery assessing cognitive rigidity in two genetic mouse models of autism. *Front Behav Neurosci*. 2014; 8:140. [PubMed: 24808839]
- Qiu S, Aldinger KA, Levitt P. Modeling of autism genetic variations in mice: focusing on synaptic and microcircuit dysfunctions. *Dev Neurosci*. 2012; 34:88–100. [PubMed: 22572629]
- Radyushkin K, Hammerschmidt K, Boretius S, Varoqueaux F, El-Kordi A, Ronnenberg A, Winter D, Frahm J, Fischer J, Brose N, Ehrenreich H. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. *Genes Brain Behav*. 2009; 8:416–425. [PubMed: 19243448]
- Rapin I, Dunn M. Update on the language disorders of individuals on the autistic spectrum. *Brain Dev*. 2003; 25:166–172. [PubMed: 12689694]
- Rausch JL, Sirota EL, Londino DL, Johnson ME, Carr BM, Bhatia R, Miller S. Open-label risperidone for Asperger's disorder: negative symptom spectrum response. *J Clin Psychiatry*. 2005; 66:1592–1597. [PubMed: 16401163]
- Reith RM, McKenna J, Wu H, Hashmi SS, Cho SH, Dash PK, Gambello MJ. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. *Neurobiol Dis*. 2013; 51:93–103. [PubMed: 23123587]
- Richdale AL. Sleep problems in autism: prevalence, cause, and intervention. *Dev Med Child Neurol*. 1999; 41:60–66. [PubMed: 10068053]
- Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. *J Neurosci*. 2009; 29:38–42. [PubMed: 19129382]
- Ritvo ER, Freeman BJ, Mason-Brothers A, Mo A, Ritvo AM. Concordance for the syndrome of autism in 40 pairs of afflicted twins. *Am J Psychiatry*. 1985; 142:74–77. [PubMed: 4038442]
- Robb AS, Andersson C, Bellocchio EE, Manos G, Rojas-Fernandez C, Mathew S, Marcus R, Owen R, Mankoski R. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6–17 years old): results from a pooled analysis of 2 studies. *Prim Care Companion CNS Disord*. 2011; 13:1.
- Rogers SJ, Estes A, Lord C, Vismara L, Winter J, Fitzpatrick A, Guo M, Dawson G. Effects of a brief early start denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2012; 51:1052–1065. [PubMed: 23021480]
- Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. *J Child Psychol Psychiatry*. 2005; 46:1255–1268. [PubMed: 16313426]
- Rojas DC, Wilson LB. gamma-band abnormalities as markers of autism spectrum disorders. *Biomark Med*. 2014; 8:353–368. [PubMed: 24712425]
- Roohi J, Montagna C, Tegay DH, Palmer LE, DeVincent C, Pomeroy JC, Christian SL, Nowak N, Hatchwell E. Disruption of contactin 4 in three subjects with autism spectrum disorder. *J Med Genet*. 2009; 46:176–182. [PubMed: 18349135]

- Rosenfeld JA, Ballif BC, Torchia BS, Sahoo T, Ravnan JB, Schultz R, Lamb A, Bejjani BA, Shaffer LG. Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders. *Genet Med*. 2010; 12:694–702. [PubMed: 20808228]
- Rouillet FI, Wohr M, Crawley JN. Female urine-induced male mice ultrasonic vocalizations, but not scent-marking, is modulated by social experience. *Behav Brain Res*. 2010; 216:19–28. [PubMed: 20540967]
- Rouillet FI, Wohr M, Crawley JN. Female urine-induced male mice ultrasonic vocalizations, but not scent-marking, is modulated by social experience. *Behav Brain Res*. 2011; 216:19–28. [PubMed: 20540967]
- Ryan BC, Young NB, Crawley JN, Bodfish JW, Moy SS. Social deficits, stereotypy and early emergence of repetitive behavior in the C58/J inbred mouse strain. *Behav Brain Res*. 2010; 208:178–188. [PubMed: 19941908]
- Ryan BC, Young NB, Moy SS, Crawley JN. Olfactory cues are sufficient to elicit social approach behaviors but not social transmission of food preference in C57BL/6J mice. *Behav Brain Res*. 2008; 193:235–242. [PubMed: 18586054]
- Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, Ohkura T, Katoh-Semba R, Nakajima M, Sekine Y, Tanaka M, Nakamura K, Iwata Y, Tsuchiya KJ, Mori N, Detera-Wadleigh SD, Ichikawa H, Itohara S, Yoshikawa T, Furuichi T. Autistic-like phenotypes in *Cadps2*-knockout mice and aberrant *CADPS2* splicing in autistic patients. *J Clin Invest*. 2007; 117:931–943. [PubMed: 17380209]
- Sahu JK, Gulati S, Sapra S, Arya R, Chauhan S, Chowdhury MR, Gupta N, Kabra M, Gupta YK, Dwivedi SN, Kalra V. Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. *J Child Neurol*. 2013; 28:570–575. [PubMed: 22752489]
- Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. *Biol Psychiatry*. 2011; 69:875–882. [PubMed: 21306704]
- Samaco RC, McGraw CM, Ward CS, Sun Y, Neul JL, Zoghbi HY. Female *Mecp2*(±) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. *Hum Mol Genet*. 2013; 22:96–109. [PubMed: 23026749]
- Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. The familial risk of autism. *JAMA*. 2014; 311:1770–1777. [PubMed: 24794370]
- Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. *Nature*. 2013; 493:411–415. [PubMed: 23263185]
- Sato A, Kasai S, Kobayashi T, Takamatsu Y, Hino O, Ikeda K, Mizuguchi M. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. *Nat Commun*. 2012; 3:1292. [PubMed: 23250422]
- Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene Arnold L, McCracken JT, Tierney E, Deng Y, Dziura J, Vitiello B. Brief report: social disability in autism spectrum disorder: results from research units on pediatric psychopharmacology (RUPP) autism network trials. *J Autism Dev Disord*. 2013; 43:739–746. [PubMed: 23104617]
- Scattoni ML, Gandhi SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+*tf/J* mouse model of autism. *PLoS ONE*. 2008; 3:e3067. [PubMed: 18728777]
- Scattoni ML, Martire A, Cartocci G, Ferrante A, Ricceri L. Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+*tf/J* strain, a mouse model of autism. *Behav Brain Res*. 2013; 251:35–40. [PubMed: 23270976]
- Scattoni ML, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in adult BTBR T+*tf/J* mice during three types of social encounters. *Genes Brain Behav*. 2010; 10:44–56.
- Scattoni ML, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in adult BTBR T+*tf/J* mice during three types of social encounters. *Genes Brain Behav*. 2011; 10:44–56. [PubMed: 20618443]

- Scearce-Levie K, Roberson ED, Gerstein H, Cholfin JA, Mandiyan VS, Shah NM, Rubenstein JL, Mucke L. Abnormal social behaviors in mice lacking Fgf17. *Genes Brain Behav.* 2008; 7:344–354. [PubMed: 17908176]
- Schmeisser MJ, Ey E, Wegener S, Bockmann J, Stempel AV, Kuebler A, Janssen AL, Udvardi PT, Shiban E, Spilker C, Balschun D, Skryabin BV, Dieck S, Smalla KH, Montag D, Leblond CS, Faure P, Torquet N, Le Sourd AM, Toro R, Grabrucker AM, Shoichet SA, Schmitz D, Kreutz MR, Bourgeron T, Gundelfinger ED, Boeckers TM. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. *Nature.* 2012; 486:256–260. [PubMed: 22699619]
- Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. *Neuropsychopharmacology.* 2005; 30:80–89. [PubMed: 15238991]
- Seese RR, Maske AR, Lynch G, Gall CM. Long-term memory deficits are associated with elevated synaptic ERK1/2 activation and reversed by mGluR5 antagonism in an animal model of autism. *Neuropsychopharmacology.* 2014; 39:1664–1673. [PubMed: 24448645]
- Shair HN, Rupert DD, Rosko LM, Hofer MA, Myers MM, Welch MG. Effects of maternal deprivation and the duration of reunion time on rat pup ultrasonic vocalization responses to isolation: possible implications for human infant studies. *Dev Psychobiol.* 2014; 57(1):63–72. [PubMed: 25380197]
- Shepard KN, Liu RC. Experience restores innate female preference for male ultrasonic vocalizations. *Genes Brain Behav.* 2011; 10:28–34. [PubMed: 20345895]
- Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. *J Autism Dev Disord.* 2012; 42:1592–1605. [PubMed: 22068820]
- Silverman JL, Crawley JN. The promising trajectory of autism therapeutics discovery. *Drug Discov Today.* 2014; 19:838–844. [PubMed: 24362109]
- Silverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. *Neuropharmacology.* 2013; 64:268–282. [PubMed: 22801296]
- Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. *Sci Transl Med.* 2012; 4:131ra151.
- Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. *Neuropsychopharmacology.* 2010a; 35:976–989. [PubMed: 20032969]
- Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. *Nat Rev.* 2010b; 11:490–502.
- Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, Crawley JN. GABAB receptor agonist r-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. *Neuropsychopharmacology.* 2015; 40:2228–2239. [PubMed: 25754761]
- Smalley SL, Asarnow RF, Spence MA. Autism and genetics. A decade of research. *Arch Gen Psychiatry.* 1988; 45:953–961. [PubMed: 3048227]
- Smith SE, Zhou YD, Zhang G, Jin Z, Stoppel DC, Anderson MP. Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in mice. *Sci Transl Med.* 2011; 3:103ra197.
- Sowers LP, Loo L, Wu Y, Campbell E, Ulrich JD, Wu S, Paemka L, Wassink T, Meyer K, Bing X, El-Shanti H, Usachev YM, Ueno N, Manak JR, Shepherd AJ, Ferguson PJ, Darbro BW, Richerson GB, Mohapatra DP, Wemmie JA, Bassuk AG. Disruption of the non-canonical Wnt gene PRICKLE2 leads to autism-like behaviors with evidence for hippocampal synaptic dysfunction. *Mol Psychiatry.* 2013; 18:1077–1089. [PubMed: 23711981]
- Spencer CM, Alekseyenko O, Hamilton SM, Thomas AM, Serysheva E, Yuva-Paylor LA, Paylor R. Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. *Autism Res.* 2011; 4:40–56. [PubMed: 21268289]

- Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. *Genes Brain Behav.* 2005; 4:420–430. [PubMed: 16176388]
- Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, Azocar F, Jain A. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. *Pediatrics.* 2013; 132:833–840. [PubMed: 24144704]
- Sperow M, Berry RB, Bayazitov IT, Zhu G, Baker SJ, Zakharenko SS. Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration. *J Physiol.* 2012; 590:777–792. [PubMed: 22147265]
- Spooren W, Lindemann L, Ghosh A, Santarelli L. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. *Trends Pharmacol Sci.* 2012; 33:669–684. [PubMed: 23084458]
- Sugimoto H, Okabe S, Kato M, Koshida N, Shiroishi T, Mogi K, Kikusui T, Koide T. A role for strain differences in waveforms of ultrasonic vocalizations during male-female interaction. *PLoS ONE.* 2011; 6:e22093. [PubMed: 21818297]
- Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A, Oishi M, Kimura T, Onaka T, Ozono K, Taniike M. Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. *J Child Adolesc Psychopharmacol.* 2013; 23:123–127. [PubMed: 23480321]
- Talebizadeh Z, Lam DY, Theodoro MF, Bittel DC, Lushington GH, Butler MG. Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism. *J Med Genet.* 2006; 43:e21. [PubMed: 16648374]
- Teng BL, Nonneman RJ, Agster KL, Nikolova VD, Davis TT, Riddick NV, Baker LK, Pedersen CA, Jarstfer MB, Moy SS. Prosocial effects of oxytocin in two mouse models of autism spectrum disorders. *Neuropharmacology.* 2013; 72:187–196. [PubMed: 23643748]
- Terranova ML, Laviola G. Scoring of social interactions and play in mice during adolescence. *Curr Protoc Toxicol.* 2005;10. Chap 13(Unit13). [PubMed: 23045110]
- The Dutch-Belgian Fragile XC. Bakker CE, Verheij C, Willemsen R, van der Helm R, Oerlemans F, Vermey M, Bygrave A, Hoozeveen A, Oostra BA, Reyniers E, De Boule K, D'Hooze R, Cras P, van Velzen D, Nagels G, Martin J-J, De Deyn PP, Darby JK, Willems PJ. Fmr1 knockout mice: a model to study fragile X mental retardation. *Cell.* 1994; 78:23–33. [PubMed: 8033209]
- Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. *Psychopharmacology.* 2009; 204:361–373. [PubMed: 19189082]
- Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. *Psychopharmacology.* 2012; 219:47–58. [PubMed: 21656124]
- Tillema JM, Leach JL, Krueger DA, Franz DN. Everolimus alters white matter diffusion in tuberous sclerosis complex. *Neurology.* 2012; 78:526–531. [PubMed: 22262746]
- Tripathi PP, Sgado P, Scali M, Viaggi C, Casarosa S, Simon HH, Vaglini F, Corsini GU, Bozzi Y. Increased susceptibility to kainic acid-induced seizures in Engrailed-2 knockout mice. *Neuroscience.* 2009; 159:842–849. [PubMed: 19186208]
- Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. *Proc Natl Acad Sci.* 2009; 106:2029–2034. [PubMed: 19208815]
- Tsai PT, Hull C, Chu Y, Greene-Colozzi E, Sadowski AR, Leech JM, Steinberg J, Crawley JN, Regehr WG, Sahin M. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. *Nature.* 2012; 488:647–651. [PubMed: 22763451]
- Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, Khalilov I, Tsintsadze V, Bouchoud C, Chazal G, Lemonnier E, Lozovaya N, Burnashev N, Ben-Ari Y. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. *Science.* 2014; 343:675–679. [PubMed: 24503856]
- Upchurch M, Wehner JM. Differences between inbred strains of mice in morris water maze performance. *Behav Genet.* 1988; 18:55–68. [PubMed: 3365197]

- Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. *Clin Neuropharmacol*. 2014; 37:69–72. [PubMed: 24824660]
- Uutela M, Lindholm J, Rantamaki T, Umemori J, Hunter K, Voikar V, Castren ML. Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome. *Front Cell Neurosci*. 2014; 8:150. [PubMed: 24904293]
- van Steensel FJ, Bogels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. *Clin Child Fam Psychol Rev*. 2011; 14:302–317. [PubMed: 21735077]
- Varni JW, Handen BL, Corey-Lisle PK, Guo Z, Manos G, Ammerman DK, Marcus RN, Owen R, McQuade RD, Carson WH, Mathew S, Mankoski R. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. *Clin Ther*. 2012; 34:980–992. [PubMed: 22444782]
- Volkmar FR, Nelson DS. Seizure disorders in autism. *J Am Acad Child Adolesc Psychiatry*. 1990; 29:127–129. [PubMed: 2295565]
- Vorstman JA, Spooren W, Persico AM, Collier DA, Aigner S, Jagasia R, Glennon JC, Buitelaar JK. Using genetic findings in autism for the development of new pharmaceutical compounds. *Psychopharmacology*. 2014; 231:1063–1078. [PubMed: 24292384]
- Wagner GC, Reuhl KR, Cheh M, McRae P, Halladay AK. A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. *J Autism Dev Disord*. 2006; 36:779–793. [PubMed: 16609825]
- Wang H, Liang S, Burgdorf J, Wess J, Yeomans J. Ultrasonic vocalizations induced by sex and amphetamine in M2, M4, M5 muscarinic and D2 dopamine receptor knockout mice. *PLoS ONE*. 2008; 3:e1893. [PubMed: 18382674]
- Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kamio Y, Kato N, Miyashita Y, Kasai K, Yamasue H. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. *JAMA Psychiatry*. 2014; 71:166–175. [PubMed: 24352377]
- Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. *PLoS ONE*. 2012; 7:e36981. [PubMed: 22615862]
- White NR, Prasad M, Barfield RJ, Nyby JG. 40- and 70-kHz vocalizations of mice (*Mus musculus*) during copulation. *Physiol Behav*. 1998; 63:467–473. [PubMed: 9523885]
- Whitney G, Coble JR, Stockton MD, Tilson EF. Ultrasonic emissions: do they facilitate courtship of mice. *J Comp Physiol Psychol*. 1973; 84:445–452. [PubMed: 4745813]
- Whitney G, Nyby JG. Cues that elicit ultrasounds from adult male mice. *Am Zool*. 1979; 19:457–464.
- Winslow JT, Shapiro L, Carter CS, Insel TR. Oxytocin and complex social behavior: species comparisons. *Psychopharmacol Bull*. 1993; 29:409–414. [PubMed: 8121969]
- Wohr M. Ultrasonic vocalizations in Shank mouse models for autism spectrum disorders: detailed spectrographic analyses and developmental profiles. *Neurosci Biobehav Rev*. 2014; 43:199–212. [PubMed: 24726578]
- Wohr M, Roullet FI, Crawley JN. Reduced scent marking and ultrasonic vocalizations in the BTBR T+^{tf/J} mouse model of autism. *Genes Brain Behav*. 2011a; 10:35–43. [PubMed: 20345893]
- Wohr M, Roullet FI, Hung AY, Sheng M, Crawley JN. Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior. *PLoS ONE*. 2011b; 6:e20631. [PubMed: 21695253]
- Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, Ha S, Chung C, Jung ES, Cho YS, Park SG, Lee JS, Lee K, Kim D, Bae YC, Kaang BK, Lee MG, Kim E. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. *Nature*. 2012; 486:261–265. [PubMed: 22699620]
- Wrenn CC. Social transmission of food preference in mice. *Curr Protoc Neurosci*. 2004:8–5. Chap 8.

- Wrenn CC, Harris AP, Saavedra MC, Crawley JN. Social transmission of food preference in mice: methodology and application to galanin-overexpressing transgenic mice. *Behav Neurosci*. 2003; 117:21–31. [PubMed: 12619904]
- Wurzman R, Forcelli PA, Griffey CJ, Kromer LF. Repetitive grooming and sensorimotor abnormalities in an ephrin-A knockout model for autism spectrum disorders. *Behav Brain Res*. 2014; 278c: 115–128.
- Yan J, Oliveira G, Coutinho A, Yang C, Feng J, Katz C, Sram J, Bockholt A, Jones IR, Craddock N, Cook EH Jr, Vicente A, Sommer SS. Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. *Mol Psychiatry*. 2005a; 10:329–332. [PubMed: 15622415]
- Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology*. 2005b; 49:1053–1066. [PubMed: 16054174]
- Yang M, Abrams DN, Zhang JY, Weber MD, Katz AM, Clarke AM, Silverman JL, Crawley JN. Low sociability in BTBR T+ tf/J mice is independent of partner strain. *Physiol Behav*. 2012a; 107:649–662. [PubMed: 22245067]
- Yang M, Bozdagi O, Scattoni ML, Wöhr M, Roullet FI, Katz AM, Abrams DN, Kalikhman D, Simon H, Woldeyohannes L, Zhang JY, Harris MJ, Saxena R, Silverman JL, Buxbaum JD, Crawley JN. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. *J Neurosci*. 2012b; 32:6525–6541. [PubMed: 22573675]
- Yang M, Clarke AM, Crawley JN. Postnatal lesion evidence against a primary role for the corpus callosum in mouse sociability. *Eur J Neurosci*. 2009; 29:1663–1677. [PubMed: 19419429]
- Yang M, Loureiro D, Kalikhman D, Crawley JN. Male mice emit distinct ultrasonic vocalizations when the female leaves the social interaction arena. *Front Behav Neurosci*. 2013; 7:159. [PubMed: 24312027]
- Yang M, Scattoni ML, Zhodzishsky V, Chen T, Caldwell H, Young WS, McFarlane HG, Crawley JN. Social approach behaviors are similar on conventional versus reverse lighting cycles, and in replications across cohorts, in BTBR T+ tf/J, C57BL/6J, and vasopressin receptor 1B mutant mice. *Front Behav Neurosci*. 2007; 1:1. [PubMed: 18958184]
- Yang M, Silverman JL, Crawley JN. Automated three-chambered social approach task for mice. *Curr Protoc Neurosci*. 2011:8–26. Chap 8.
- Young LJ, Pitkow LJ, Ferguson JN. Neuropeptides and social behavior: animal models relevant to autism. *Mol Psychiatry*. 2002; 7(Suppl 2):S38–S39. [PubMed: 12142945]
- Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. *Hum Mol Genet*. 2011; 20:445–454. [PubMed: 21062901]
- Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Ann Neurol*. 2008; 63:444–453. [PubMed: 18389497]
- Zhang WQ, Smolik CM, Barba-Escobedo PA, Gamez M, Sanchez JJ, Javors MA, Daws LC, Gould GG. Acute dietary tryptophan manipulation differentially alters social behavior, brain serotonin and plasma corticosterone in three inbred mouse strains. *Neuropharmacology*. 2015; 90:1–8. [PubMed: 25445490]
- Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, Powell CM, Parada LF. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. *J Neurosci*. 2009; 29:1773–1783. [PubMed: 19211884]
- Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. *Cold Spring Harb Perspect Biol*. 2012; 4(3):a009886. [PubMed: 22258914]

Table 1

Examples of preclinical and clinical evaluations of drug treatments for autism

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
mGluR5 modulation	BTBR C58/J	MPEP MTEP GRN529	<ul style="list-style-type: none"> Improved sociability Reduced repetitive behavior Improved cognition 	Silverman et al. (2010a), Silverman et al. (2012) and Seese et al. (2014)
	<i>Fmr1</i>	AFQ056 CTEP MTEP MPEP Fenobam JNJ16259685	<ul style="list-style-type: none"> Rescued abnormal dendritic spine morphology Corrected excessive protein synthesis Normalized altered long-term depression Reduced seizure susceptibility Decreased hyperactivity Rescued cognitive deficits Rescued sensorimotor gating Reduced repetitive behavior 	Yan et al. (2005b), De Vrij et al. (2008), Busquets-Garcia et al. (2013), Michalon et al. (2012), Gantois et al. (2013), Thomas et al. (2012), Gandhi et al. (2014) and Pop et al. (2014)
	<i>Shank2</i>	CDPPB	<ul style="list-style-type: none"> Restored abnormal long-term potentiation and long-term depression Improved sociability 	Won et al. (2012)
	Valproic acid	MPEP	Reduced repetitive behavior	Mehia et al. (2011)
	Clinical population	Treatment	Phase	Reference*
	ASD—5 to 17 years old	Acamprosate	Phases 2 and 3; single-blind placebo lead-in trial	NCT01813318; Erickson et al. (2014b)
	ASD—6 to 13	Acamprosate	Open label	Erickson et al. (2011a)
	Fragile X males with ASD—18 to 23 years old	Acamprosate	Open label	Erickson et al. (2010)
	Fragile X—5 to 17 years old	Acamprosate	Phase 3; open label	NCT01300923; Erickson et al. (2013)
	Fragile X—3 to 11 years old	AFQ056	Phase 1	NCT01482143

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
GABA _B modulation	Fragile X—12 to 17 years old	AFQ056	Phases 2 and 3	NCT01357239, NCT01433354
	Fragile X—18 to 45 years old	AFQ056	Phase 2	NCT01253629, NCT01348087, NCT00718341
	Fragile X—5 to 13 years old	RO4917523	Phase 2	NCT01750957
	Fragile X—14 to 50 years old	RO4917523	Phase 2	NCT01517698, NCT01015430
	BTBR C58/J	R-Baclofen	<ul style="list-style-type: none">Improved sociabilityReduced repetitive behavior	Silverman et al. (2015)
	<i>Fmr1</i>	STX209 (Arbaclofen)	<ul style="list-style-type: none">Normalized normal dendritic spine morphologyCorrected excessive protein synthesisReduced seizure susceptibility	Henderson et al. (2012)
	NMDA NR1 subunit knockout mice	Racemic baclofen	<ul style="list-style-type: none">Improved excitation/inhibition balanceRescued gamma EEG band deficitsReduced hyperactivityRescued sensorimotor gating deficits	Gandal et al. (2012)
	Clinical population	Treatment	Phase	Reference*
	ASD—5 to 21 years old	STX209 (Arbaclofen)	Phases 2 and 3	NCT01706523, NCT01288716; Frye (2014)
	ASD—6 to 17 years old	STX209 (Arbaclofen)	Phase 2; open label	NCT00846547; Erickson et al. (2014a) and Frye (2014)
GABA _A modulation	Fragile X—6 to 40 years old	STX209 (Arbaclofen)	Phase 2	NCT00788073; Berry-Kravis et al. (2012)
	Fragile X—12 to 50 years old	STX209 (Arbaclofen)	Phase 3	NCT01282268
	BTBR	Diazepam Low dose of benzodiazepines L-838,417	<ul style="list-style-type: none">Increased GABAergic inhibitory neurotransmissionImproved social interactions	Pobbe et al. (2011) and Han et al. (2014)

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
mTOR inhibitors			<ul style="list-style-type: none"> Ameliorated cognitive deficits 	
	Clinical population	Treatment	Phase	Reference*
	ASD—18 to 45 years old	Pregnanolone	Phase 2	NCT01881737
	High functioning ASD—18 to 35 years old	AZ7325	Phase 2	NCT01966679
	BTBR	Rapamycin	<ul style="list-style-type: none"> Improved sociability 	Burket et al. (2014)
	<i>Pten</i>	Rapamycin RAD001 (Everolimus)	<ul style="list-style-type: none"> Improved macrocephaly Inhibits neuronal hypertrophy Improved abnormal sociability Reduced seizures 	Zhou et al. (2009)
	<i>Tsc1</i>		<ul style="list-style-type: none"> Improved survival rates and weight gain Prevented seizures Ameliorated abnormal EEG Improved neuronal morphology Prevented cell loss Restored myelination abnormalities Improved motor phenotypes Improved sociability Ameliorated cognitive deficits 	Meikle et al. (2008), Zeng et al. (2008), Sato et al. (2012) and Tsai et al. (2012)
	<i>Tsc2</i>		<ul style="list-style-type: none"> Improved cognition Improved sociability 	Ehninger et al. (2008) and Sato et al. (2012)
	<i>Fmr1</i>	Tensirolimus	<ul style="list-style-type: none"> Rescued cognitive impairment Reduced seizure susceptibility 	Busquets-Garcia et al. (2013)
	Clinical population	Treatment	Phase	Reference*

Mechanistic class	Predclinical model	Compound	Predclinical phenotype rescues	Reference
Neuropeptides	Tuberous sclerosis complex—4 to 15 years old	Rapamycin (Sirolimus) RAD001 (Everolimus)	Phases 2 and 3	NCT01730209
	Tuberous sclerosis complex—2 to 61 years old		Phases 1, 2, and 3	NCT01929642, NCT00789828, NCT00790400, NCT00411619; Krueger et al. (2010), Tillema et al. (2012), Bissler et al. (2013) and Franz et al. (2013), Krueger et al. (2013)
	BTBR	Oxytocin	• No behavioral effects	Bales et al. (2014)
	C57BL6/J		• Reduced several social behaviors	Huang et al. (2014)
	C58/J		• Improved sociability	Teng et al. (2013)
	Oxytocin knockout mice		• Improved sociability	Ferguson et al. (2001)
Growth factors	Oxytocin receptor mice		• Improved sociability • Restored cognitive inflexibility	Sala et al. (2011)
	Clinical population	Treatment	Phase	Reference*
	ASD—3 to 17 years old	Oxytocin	Phases 2 and 3	NCT01944046, NCT01308749, NCT01624194; Tachibana et al. (2013)
	ASD—12 to 17 years old			NCT01417026, NCT02090829, NCT01931033, NCT02007447, ACTRN12609000513213; Guastella et al. (2014)
	ASD—18 to 60 years old			NCT00490802, NCT01337687, NCT01788072; Hollander et al. (2003) and Lin et al. (2014)
	ASD—21 to 38 years old			UMIN000002241, UMIN000004393; Aoki et al. (2014a, b) and Watanabe et al. (2014)
	ASD—19 to 56 years old		Randomized cross-over double-blind study	Hollander et al. (2007)
	ASD—6 to 12 years old	Vasopressin	Phase 2	NCT01962870
	ASD—18 to 55 years old	RG-7314	Phase 2	NCT01793441
	<i>Fmr1</i>	BDNF	• Rescued long-term potentiation abnormalities	Lauterborn et al. (2007)

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
NMDA glutamate receptor modulation	<i>Shank3</i>	IGF1	• Improved long-term potentiation	Bozdagi et al. (2013)
	<i>Mecp2</i> ^{-/-}		• Reversed respiration deficits	Tropea et al. (2009)
	Clinical population	Treatment	Phase	Reference*
	ASD—5 to 12 years old	IGF1	Phase 2	NCT01970345
	22q13 deletion (Phelan-McDermid syndrome)			NCT01525901
	Rett syndrome—4 to 11 years old	IGF1	Pilot study; case study	Pini et al. (2012, 2014)
	<i>Fmr1</i>	Memantine	• Corrected spine morphology	Wei et al. (2012)
	<i>Shank2</i>	D-cycloserine	• Improved sociability	Won et al. (2012)
	Clinical population	Treatment	Phase	Reference
	ASD—3 to 12 years old	D-cycloserine	Phase 3; Prospective, open label study	NCT00198120; Owley et al. (2006)
AMPA glutamate receptor modulation	ASD—14 to 25 years old		Pilot study; double-blind randomized trial	Posey et al. (2004) and Urbano et al. (2014)
	ASD—2 to 26 years old	Memantine	Open label; retrospective study	Chez et al. (2007) and Erickson et al. (2007)
	ASD—6 to 12 years old		Phase 2	NCT01592786, NCT01592773
	ASD—13 to 17 years old		Phase 3	NCT01972074
	ASD—18 to 85 years old		Phase 4	NCT01078844, NCT01333865
	BTBR	AMPAkines CX546 CX1837 CX1739	• Improved facets of sociability	Silverman et al. (2013)
	<i>Mecp2</i>		• Reversed respiration deficits	Ogier et al. (2007)
	Clinical population	Treatment	Phase	Reference*
Atypical antipsychotics	Fragile X or ASD—18 to 50 years old	CX516	Phase 2	NCT00054730; Berry-Kravis et al. (2006)
	BTBR	Risperidone M100907	• Improved reversal learning	Amodeo et al. (2014a)
		Risperidone	• Failed to improve sociability	Chadman (2011) and Gould et al. (2011)

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
Serotonin reuptake inhibitors	<i>Cntnap2</i>	Risperidone	<ul style="list-style-type: none"> • Reduced hyperactivity • Decreased repetitive behavior 	Penagarikano et al. (2011)
	Clinical population	Treatment	Phase	Reference*
	ASD—30 months to 17 years old	Aripiprazole	Phase 2, 3 and 4	NCT00619190, NCT01617447, NCT00337571, NCT02069977, NCT00198107
	ASD—12 to 18 years old	Aripiprazole	Phase 2	NCT00208533
		Ziprasidone	Phase 2	NCT00208559
	ASD—5 to 18 years old	Aripiprazole	Phases 3 and 4; Pilot study; Open label, Chart review	NCT00332241, NCT00337571, NCT01227668, NCT00365859, Marcus et al. (2009), Owen et al. (2009), Blankenship et al. (2010), Marcus et al. (2011a, b), Robb et al. (2011), Varni et al. (2012), Ishitobi et al. (2013), Mankoski et al. (2013), Findling et al. (2014), Maloney et al. (2014) and Adler et al. (2015)
		Risperidone	Phases 2, 3, and 4; Open label; Randomized, double-blind trial	NCT01171937, NCT00576732, NCT01624675, NCT0005014; McDougle et al. (2000), McCracken et al. (2002), McDougle et al. (2005), Rausch et al. (2005), Desousa et al. (2010), Handen et al. (2013), Kent et al. (2013a, b), Scahill et al. (2013), Ghaelt et al. (2014) and Ghanizadeh and Ayoobzadehshirazi (2015)
		Lurasidone	Phase 3	NCT01911442
	Fragile X—6 to 25 years old	Aripiprazole	Open label	Erickson et al. (2011b)
	BTBR	Buspirone	<ul style="list-style-type: none"> • Enhanced social interactions 	Gould et al. (2011)
		Fluoxetine	<ul style="list-style-type: none"> • Increased sociability 	Chadman (2011) and Gould et al. (2011)
	<i>Fmr1</i>		<ul style="list-style-type: none"> • Reduced anxiety • Reduced locomotor activity 	Ututela et al. (2014)
	Clinical population	Treatment	Phase	Reference*
	ASD—2 to 6 years old	Buspirone	Phase 2	NCT00873509
	ASD—6 to 17 years old		Open label	NCT01850355, IRCT201307303930N28; Ghanizadeh and Ayoobzadehshirazi (2015)

Mechanistic class	Preclinical model	Compound	Preclinical phenotype rescues	Reference
Acetylcholine modulation	ASD—5 to 17 years old	Citalopram	Phase 2; Randomized controlled trial	NCT00086645; NCT00211770; King et al. (2009)
		Fluoxetine	Phase 3; Open label; Placebo-controlled crossover trial	NCT00515320; ACTRN12608000173392; Buchsbaum et al. (2001), Hollander et al. (2005), Desousa (2010), Chantiluke et al. (2014a, b) and Moutt et al. (2014)
	ASD—3 to 10 years old	Fluvoxamine Sertraline	Phase 3	NCT00655174
	ASD—3 to 12 years old	Olanzapine	Phase 2	NCT00057408
	ASD—6 to 16 years old		Open pilot study; double-blind, placebo-controlled trial	Potenza et al. (1999), Malone et al. (2001), Kemner et al. (2002) and Hollander et al. (2006)
	ASD—18 to 39 years old	Sertraline	Open label	McDougle et al. (1998)
	ASD—18 to 53 years old	Fluvoxamine	Double-blind, placebo-controlled trial	McDougle et al. (1996)
	ASD—18 to 65 years old	Fluoxetine	Double-blind, placebo-controlled trial; open trial	NCT00027404; Fatemi et al. (1998) and Hollander et al. (2012)
	Fragile X—12 to 50 months old	Sertraline	Retrospective chart review	Indah Winami et al. (2012)
	BTBR	Donepezil	<ul style="list-style-type: none"> Improved cognitive flexibility Enhanced sociability 	Karvat and Kimchi (2014)
	Valproic acid		<ul style="list-style-type: none"> Improved sociability Reduced repetitive behavior Reduced hyperactivity 	Kim et al. (2014a)
	Clinical population	Treatment	Phase	Reference*
	ASD—22 to 44 months	Donepezil	Phase 2	NCT01887132
	ASD—2 to 7 years old		Open label	Buckley et al. (2011)
	ASD—7 to 19 years old		Double-blind, placebo-controlled trial	Hardan and Handen (2002) and Handen et al. (2011)
	ASD—10 to 18 years old		Phase 4	NCT01098383
	ASD—4 to 12 years old	Mecamylamine	Phase 2	NCT00773812; Arnold et al. (2012)
	Fragile X males—6 to 15 years old	Donepezil	Randomized, double-blind, placebo-controlled pilot study	CTRI-2008-000229; Sahu et al. (2013)

Identifier numbers for clinical trials were indexed from clinicaltrials.gov (NCT), anzctr.org.au (ACTRN), umin.ac.jp/ctr (UMIN), rct.ir (IRCT), and ctri.nic.in/Clinicaltrials (CTRI) Web sites

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript